Pulmonary Symptoms and Psychological Distress as Correlates and Mediators of Quality of Life in Lung Transplant Recipients: A Cross- sectional Study

Pulmonary Symptoms and Psychological Distress as Correlates and Mediators of Quality of Life in Lung Transplant Recipients: A Cross- sectional Study | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Pulmonary Symptoms and Psychological Distress as Correlates and Mediators of Quality of Life in Lung Transplant Recipients: A Cross- sectional Study Stańska Aleksandra, Karolak Wojciech, Żegleń Sławomir, Wojarski Jacek This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8290982/v1 This work is licensed under a CC BY 4.0 License Status: Under Review Version 1 posted 7 You are reading this latest preprint version Abstract Background: Lung transplant recipients often live for years with residual respiratory symptoms and psychological distress, but the pathways through which these factors affect quality of life (QoL) are not fully understood. We examined how transplant-specific pulmonary symptom burden and psychological distress relate to generic and transplant-specific QoL in long-term lung transplant recipients. Methods: In this cross-sectional study, 76 adult lung transplant recipients from a single centre completed the Lung Transplant Quality of Life (LT-QoL) questionnaire, EQ-5D-5L, SF-36, St George’s Respiratory Questionnaire (SGRQ) and Hospital Anxiety and Depression Scale (HADS). A composite psychological distress index was derived from HADS-Anxiety, HADS-Depression and the LT-QoL Anxiety/Depression and Health Distress subscales. Associations were examined using Pearson correlations, hierarchical linear regression (adjusting for age, sex and time since transplant) and mediation models with psychological distress as a mediator between pulmonary symptoms and QoL outcomes. Results: Pulmonary symptom burden (LT-QoL Pulmonary Symptoms) was in the low-moderate range yet showed robust correlations with poorer generic, transplant-specific and respiratory-specific QoL (|r| up to .82). The psychological distress index demonstrated good internal consistency (α = .84) and was strongly associated with worse EQ-5D, SF-36 and LT-QoL General QoL scores. In regression models, pulmonary symptoms and psychological distress independently predicted SF-36 overall QoL (R² = .55), whereas psychological distress was the stronger predictor of EQ-5D Index Value. Mediation analyses indicated that psychological distress partially mediated the association between pulmonary symptoms and SF-36 and EQ-5D Index Value, while effects on EQ-VAS and LT-QoL General QoL were largely direct. Conclusions: Even modest pulmonary symptom burden and psychological distress are tightly linked to QoL years after lung transplantation. Routine follow-up should include brief assessment of both domains, and integrated care models that combine optimisation of pulmonary status with targeted psychological support may be needed to preserve long-term QoL in lung transplant recipients. Anxiety Depression Lung Transplantation Quality of Life Patient-Reported Outcome Measures Background Lung transplantation is a life-saving treatment for selected patients with end-stage respiratory disease, but long-term outcomes extend well beyond survival [1-3,26,27]. Recipients often live for many years with a complex burden of residual symptoms, treatment-related side effects, and psychosocial challenges, all of which can substantially affect health-related quality of life (HRQoL) [1-3]. Even in clinically stable patients with satisfactory graft function, limitations in physical capacity, persistent respiratory complaints, and chronic treatment burden may compromise daily functioning and subjective well-being [1-4]. As a result, international guidelines increasingly emphasize that routine follow-up after lung transplantation should include systematic assessment of patient-reported outcomes (PROs) such as symptoms and QoL, not only traditional clinical or physiological parameters [2,27]. Systematic reviews highlight substantial heterogeneity in concepts, instruments, and timing of HRQoL assessments after LTx, which complicates synthesis and benchmarking across studies [1,4,5]. Respiratory symptoms remain central to patients’ post-transplant experience. Dyspnea, cough, and activity-related breathing discomfort may persist despite objectively improved lung function [1-4]. These symptoms can reflect chronic allograft dysfunction, comorbid disease, deconditioning, or treatment-related factors, and they are strongly linked to limitations in physical and social functioning [1-4]. Disease-specific instruments such as the Lung Transplant Quality of Life (LT-QoL) questionnaire and the St George’s Respiratory Questionnaire (SGRQ) were developed to capture such symptom burden and its impact on daily life in a more granular way than generic QoL measures [7-9]. However, less is known about how transplant-specific symptom burden relates simultaneously to generic QoL indices, disease-specific respiratory health status, and transplant-specific global QoL within the same cohort [1-4,7]. Psychological factors are another key component of post-transplant outcomes. Anxiety, depressive symptoms, and health-related worry are common after solid organ transplantation and have been consistently associated with poorer QoL, greater functional impairment, and worse perceived health status [3,6,18-23,32]. A recent overview of systematic reviews concluded that although a range of psychological interventions and self-adjustment strategies appear promising for lung transplant recipients, the overall methodological quality of the evidence remains modest [6]. In lung transplant recipients, psychological distress may arise from pre-transplant disease trajectories, prolonged hospitalization, fear of rejection or infection, and chronic treatment demands [3,6,18-23]. Screening tools such as the Hospital Anxiety and Depression Scale (HADS) are widely used to quantify anxiety and depressive symptoms in this population [15-17]. In addition, transplant-specific instruments like the LT-QoL include domains that capture health-related distress and emotional reactions to life after transplantation [7,33]. Despite this, the extent to which psychological distress helps to explain the impact of ongoing pulmonary symptom burden on QoL after lung transplantation is not fully understood [3,6,18-23,32]. Most previous studies have examined either the association between respiratory status and QoL or the association between psychological distress and QoL, often focusing on a single generic measure such as the SF-36 or EQ-5D [1-4,10-12,16,18,25,26]. Fewer analyses have integrated disease-specific symptom burden, transplant specific QoL, generic QoL, and psychological distress within a single analytic framework. In particular, it remains unclear whether the relationship between pulmonary symptoms and QoL is largely direct, or whether it is partly transmitted through heightened psychological distress [3,6,18-23,32]. Understanding these pathways is clinically important, because it may clarify whether interventions should focus primarily on symptom control, on psychological support, or on both in combination. The present study addresses this gap by examining how transplant-specific pulmonary symptom burden relates to multiple indicators of QoL in a cohort of adult lung transplant recipients, and by testing the mediating role of psychological distress. Using the Polish adaptation of the LT-QoL questionnaire together with the EQ-5D, SF-36, SGRQ, and HADS [7-9,10-12-14,15-17], we first describe the levels of symptom burden, psychological distress, and QoL in this sample and their bivariate associations. We then use hierarchical regression models to evaluate the independent contributions of pulmonary symptoms and psychological distress to generic and transplant specific QoL, controlling for age, sex, and time since transplantation. Finally, we apply mediation models to test whether psychological distress statistically mediates the association between pulmonary symptom burden and different QoL outcomes. These analyses are based on the same clinical cohort that was previously used for the linguistic and psychometric validation of the Polish LT-QoL [preprint, in review; 33], but the present work addresses distinct mechanistic questions about the interplay between symptoms, psychological distress, and QoL after lung transplantation. Methods Study design and participants This cross-sectional study was conducted in adult lung transplant recipients followed at the University Clinical Center in Gdańsk, Poland. The present analyses are based on the same clinical cohort that was used for the linguistic and psychometric validation of the Polish version of the LT-QoL questionnaire, reported in detail elsewhere [33]. The validation paper focused on translation procedures, factor structure and reliability of the LT-QoL. In contrast, the current study addressed distinct, pre-specified research questions about associations between pulmonary symptom burden, psychological distress and multiple indicators of quality of life. None of the regression or mediation models, hypotheses or outcome tables presented here were reported in the validation paper, so there is no overlap in the main analytic results. Eligible participants were adult lung transplant recipients who were attending routine outpatient follow-up during the recruitment period. Consecutive patients seen in the transplant clinic were invited to participate. In addition, patients without a scheduled visit in the near future were contacted by telephone or e-mail and could complete the questionnaires electronically or on paper and return them by post. A total of 76 lung transplant recipients provided core sociodemographic and clinical data (age, sex, time since transplantation). Due to missing questionnaire responses, some analyses were conducted on slightly smaller subsamples; exact sample sizes for each instrument and analysis are reported in the tables. For the main analyses linking pulmonary symptoms, psychological distress, and quality of life, 67 participants had complete data for the LT-QoL Pulmonary Symptoms subscale, the psychological measures, and at least one quality of life outcome. Participation was voluntary. Patients provided informed consent prior to completing the questionnaires, either in written form (for paper questionnaires completed during clinic visits) or orally/electronically (for questionnaires completed remotely). The study was exploratory and non-interventional and relied exclusively on anonymized self-report data. The study was conducted in accordance with the principles of the Declaration of Helsinki. Measures All questionnaires used in this study were previously developed and validated instruments; no study-specific questionnaire was created for this project. The LT-QoL, EQ-5D-5L, SF-36, SGRQ and HADS were used in their validated Polish versions as referenced below. Sociodemographic and clinical variables Age, sex, and time since lung transplantation (in months) were extracted from medical records and treated as covariates in all multivariable models. Lung Transplant Quality of Life Questionnaire (LT-QoL) Disease specific quality of life and symptom burden were assessed with the Polish version of the Lung Transplant Quality of Life (LT-QoL) questionnaire, originally developed by Singer and colleagues for lung transplant recipients [7,33]. The LT-QoL covers a broad range of domains relevant after lung transplantation, including symptom burden, functional limitations, emotional concerns, and overall quality of life [7,33]. It comprises first order subscales assessing specific domains such as Pulmonary Symptoms (Shortness of Breath, Cough), Gastrointestinal Symptoms, Neuromuscular Symptoms, Treatment Burden, Worry About Future Health, Cognitive Limitations, Sexual Problems, Anxiety and Depression, Health Distress, and General Quality of Life [7]. Several second order composite scales (for example Pulmonary Symptoms, Gastrointestinal Symptoms, Anxiety/Depression) can be derived by averaging conceptually related subscales. In the present study, two LT-QoL domains were of primary interest: LT-QoL Pulmonary Symptoms : a composite index capturing the severity of respiratory symptoms, calculated as the mean of the Shortness of Breath and Cough subscales. Scores range from 1 to 5, with higher scores indicating more severe pulmonary symptom burden. LT-QoL General Quality of Life : a single subscale assessing overall quality of life after lung transplantation. Unlike the symptom-oriented LT-QoL scales, higher scores on this subscale indicate better global quality of life (range 1 to 5). In addition, two emotion-related LT-QoL subscales: Anxiety/Depression and Health Distress , were used as transplant-specific indicators of emotional burden and entered, together with HADS-Anxiety and HADS-Depression, into the composite psychological distress index (see Statistical analyses) [7,15-17,33]. All LT-QoL items and subscales were scored according to the original authors’ recommendations [7]. The linguistic adaptation and psychometric validation of the Polish LT-QoL are described in detail elsewhere; the present work uses the same scoring rules to ensure full comparability with prior studies [33]. Hospital Anxiety and Depression Scale (HADS) Psychological symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS), a widely used 14-item screening instrument designed for use in medical settings [15,16]. The HADS consists of two seven-item subscales measuring anxiety (HADS Anxiety) and depressive symptoms (HADS Depression). Items are rated on 4-point scales from 0 to 3, yielding subscale scores from 0 to 21, with higher scores indicating more severe symptomatology. The officially adapted Polish version of the HADS was used. Previous Polish validation studies have demonstrated satisfactory internal consistency, factorial validity, and convergent validity in medical and non-medical populations [17]. In the present study, HADS Anxiety and HADS Depression scores were calculated according to standard scoring rules, without any modifications. Psychological distress index To capture overall psychological distress in a way that integrates symptom-specific and transplant-specific emotional burden, a composite psychological distress index was constructed. Four indicators were used: HADS Anxiety HADS Depression LT-QoL Anxiety/Depression subscale LT-QoL Health Distress subscale First, each of the four subscales was z standardized (mean 0, standard deviation 1). The psychological distress index was then calculated as the mean of these four z scores, with higher values indicating greater psychological distress. Internal consistency of the four indicators used to derive the psychological distress index was good. In the current sample ( N = 67 with complete data), Cronbach’s alpha based on standardized subscale scores was 0.84, and inter-correlations among the indicators ranged from r = .34 to r = .74, supporting the use of a single composite index. Conceptually, the composite index was intended to capture a transdiagnostic dimension of emotional burden that cuts across anxiety, depressive symptoms and transplant-specific health-related worry, rather than focusing on any single symptom cluster. Combining generic (HADS) and transplant specific (LT-QoL) indicators was expected to improve content validity and reduce measurement error associated with any one scale. In a sensitivity analysis we also examined models with HADS Anxiety and HADS Depression entered as separate mediators. Given the largely similar pattern of findings and the more parsimonious nature of the composite index, we retained the psychological distress index as the primary mediator in the main analyses. EQ-5D-5L Generic health status was assessed using the EQ-5D 5L, developed by the EuroQol Group [12]. The EQ-5D-5L describes health across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels of severity. These five responses form a five-digit health state profile. In addition, respondents rate their current overall health on a visual analogue scale (EQ-VAS) from 0 (worst imaginable health) to 100 (best imaginable health) [12]. For the present study, EQ-5D-5L health states were converted into a single index value (EQ-5D Index Value) using the Polish value set based on time trade off valuations in a representative national sample [13,14]. Higher EQ-5D Index Value and EQ-VAS scores indicate better overall health status. The Polish adaptation and value set studies have shown good measurement properties and support use of EQ-5D-5L in clinical and population research in Poland. SF-36 Health Survey Global health-related quality of life was measured using the Polish version of the 36 Item Short Form Health Survey (SF-36) [10,11]. The SF-36 covers eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health [10]. Items are scored and transformed to 0-100 scales, where higher scores typically indicate better health. Following the Polish scoring approach proposed by Tylka [11], items were first recoded using the Polish SF-36 key so that higher item scores reflect more negative evaluations or more frequent complaints. For each of the eight domains, item scores were summed and linearly transformed to a 0 to 100 scale, with higher domain scores indicating poorer health-related quality of life. To obtain a global index, we calculated the arithmetic mean of the eight domain scores, referred to in this study as the SF-36 overall health-related QoL score, where higher values indicate worse health status. This composite index was used as the primary SF-36 outcome in correlational, regression and mediation analyses. St George’s Respiratory Questionnaire (SGRQ) Disease-specific respiratory health-related quality of life was assessed with the St George’s Respiratory Questionnaire (SGRQ) [8,9]. The SGRQ yields three component scores (Symptoms, Activity, Impacts) and a Total score, each ranging from 0 to 100, where higher scores denote more severe respiratory health impairment [8]. The officially adapted Polish version of the SGRQ was administered and scored according to the SGRQ manual. In the current study, the SGRQ Total score was used descriptively and in bivariate analyses as a disease specific comparator for LT-QoL Pulmonary Symptoms; due to the smaller subsample with available SGRQ data, it was not included in multivariable regression or mediation models. Statistical analyses All analyses were conducted using IBM SPSS Statistics version 23 and JASP version 0.95.4. Statistical significance was set at p < .05 (two tailed). Analyses were based on available cases. For descriptive statistics and correlations, pairwise non-missing data were used; for regression and mediation models, listwise deletion was applied for the variables in each model. Exact sample sizes are reported in the tables. First, descriptive statistics were calculated for all variables, including means, standard deviations, and observed ranges for continuous variables and counts and percentages for categorical variables. Internal consistency of the indicators that formed the psychological distress index (HADS Anxiety, HADS Depression, LT-QoL Anxiety/Depression, LT-QoL Health Distress) was evaluated using Cronbach’s alpha based on standardized scores. Pearson correlation coefficients were computed to examine bivariate associations between pulmonary symptom burden (LT-QoL Pulmonary Symptoms), HADS Anxiety, HADS Depression, the psychological distress index, generic and transplant specific quality of life measures (EQ-5D Index Value, EQ-VAS, LT-QoL General Quality of Life, SF-36 overall score), and SGRQ Total. To assess the independent contributions of pulmonary symptoms and psychological distress to quality of life, hierarchical linear regression analyses were performed for four outcomes: EQ-5D Index Value, EQ-VAS, LT-QoL General Quality of Life, and the SF-36 overall score. For each outcome, age, sex, and time since transplantation (months) were entered as covariates in block 1. LT-QoL Pulmonary Symptoms (pulmonary symptom burden) was entered in block 2, and the psychological distress index was added in block 3. For each final model, unstandardized regression coefficients (B), standard errors, standardized coefficients (β), p values, and model fit indices (R², adjusted R², F, p) were reported. To further elucidate the interplay between pulmonary symptoms, psychological distress, and quality of life, mediation models were estimated using structural equation modeling in JASP (version 0.95.4). In these models, pulmonary symptom burden was represented by the LT-QoL Pulmonary Symptoms (predictor), psychological distress by the psychological distress index (mediator), and quality of life by each of the four outcomes (EQ-5D Index Value, EQ-VAS, LT-QoL General Quality of Life, and the SF-36 overall score) in turn. Age, sex, and time since transplantation were included as covariates and were allowed to predict the predictor, the mediator, and each outcome. Parameters were estimated using maximum likelihood. For each path, we report maximum-likelihood point estimates, standard errors, z values and p values, and 95% bias-corrected bootstrap confidence intervals based on 5000 resamples. For indirect effects, statistical significance was evaluated primarily based on the bootstrap confidence intervals; indirect effects were considered statistically significant when the 95% confidence interval did not include zero. As a sensitivity analysis, an additional parallel mediator model was estimated in which the HADS Anxiety and HADS Depression subscale scores were entered as separate mediators between pulmonary symptom burden and quality of life outcomes. This model was used to explore whether anxiety and depressive symptoms contributed differentially to the associations of pulmonary symptom burden with quality of life. Given the largely similar pattern of findings and the more parsimonious nature of the composite psychological distress index, detailed results of the parallel mediator model are summarized narratively rather than tabulated. Given the exploratory nature of the study and the modest sample size, we did not apply formal corrections for multiple testing. Instead, we interpreted patterns of associations across outcomes and models rather than relying on isolated p values close to the 0.05 threshold. The mediation models were estimated in cross-sectional data and are therefore intended to identify statistical indirect effects that are consistent with theoretically plausible pathways, rather than to establish causal mediation or temporal ordering. Results Sample characteristics The final sample comprised 76 lung transplant recipients (55 men, 72.4%, and 21 women, 27.6%). The mean age was M = 57.57 years ( SD = 12.92, range 25 to 77), and the mean time since lung transplantation was M = 56.59 months ( SD = 30.35, range 33 to 197; Table 1). On the transplant specific LT-QoL Pulmonary Symptoms subscale (higher scores indicating more severe respiratory symptoms), the mean score was low to moderate ( M = 2.05, SD = 0.89, range 1.00 to 5.00). The psychological distress index, a standardized composite of HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress subscales (each z-standardized and then averaged), was centered around zero ( M = 0.00, SD = 0.82, range -1.00 to 2.17). Generic health-related quality of life was relatively preserved: mean EQ-5D Index Value was M = 0.92 ( SD = 0.12), and mean EQ-5D VAS was M = 75.21 ( SD = 18.17). Transplant-specific general quality of life (LT-QoL General QoL) was also high ( M = 4.18, SD = 0.92). Higher scores on the SF-36 overall health-related QoL index and on the SGRQ Total score reflected worse health status; mean SF-36 overall score was M = 54.17 ( SD = 29.82) and mean SGRQ Total score was M = 10.14 ( SD = 6.91, N = 37). Sample sizes varied across measures due to missing questionnaire data; exact n values for each variable are reported in Table 1. Table 1. Sample characteristics and descriptive statistics. Variable n Minimum Maximum M SD Age (years) 76 25.00 77.00 57.57 12.92 Time since lung transplantation (months) 76 33.00 197.00 56.59 30.35 LT-QoL Pulmonary Symptoms (1 to 5; higher = more symptoms) 67 1.00 5.00 2.05 0.89 Psychological distress index¹ 67 -1.00 2.17 0.00 0.82 EQ-5D Index Value (0 to 1; higher = better) 67 0.38 1.00 0.92 0.12 EQ-5D VAS (0 to 100; higher = better) 67 15.00 100.00 75.21 18.17 LT-QoL General Quality of Life (1 to 5; higher = better) 67 1.00 5.00 4.18 0.92 SF-36 overall health related QoL² 66 7.00 125.00 54.17 29.82 SGRQ Total (0 to 100; higher = worse) 37 0.52 29.57 10.14 6.91 Categorical variable Category n (%) Sex Male 55 (72.4) Female 21 (27.6) Notes. ¹ Psychological distress index is a standardized composite score derived from HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress (each subscale was z-standardized and then averaged; higher scores indicate greater distress). ² Higher SF-36 overall scores reflect worse health related quality of life. Primary indications for lung transplantation in this clinical cohort were similar to those reported in our previous LT-QoL validation study from the same center [33]. In that validation sample, the most frequent indications were chronic obstructive pulmonary disease (27 patients, 38.6%) and idiopathic pulmonary fibrosis (15, 21.4%), followed by allergic alveolitis (6, 8.6%), pulmonary arterial hypertension (6, 8.6%), post-COVID-19 respiratory failure (5, 7.1%), sarcoidosis (3, 4.3%), systemic sclerosis (2, 2.9%), rheumatoid arthritis (2, 2.9%), histiocytosis (1, 1.4%), silicosis (1, 1.4%), and other rare interstitial or occupational lung diseases (2, 2.9%). The present analytic sample is nested within this clinical cohort and therefore reflects a comparable diagnostic spectrum. Bivariate associations Pearson correlations are presented in Table 2. Higher pulmonary symptom burden was consistently associated with more psychological symptoms and poorer quality of life. Pulmonary symptom burden correlated positively with HADS-Anxiety ( r = .29, p = .018) and HADS-Depression ( r = .39, p = .001), as well as with the psychological distress index ( r = .31, p = .011). Greater symptom burden was related to worse generic QoL on both EQ-5D measures (EQ-5D Index Value: r = -.38, p = .001; EQ-5D VAS: r = -.65, p < .001) and to lower transplant specific general QoL ( r = -.43, p < .001). Regarding the generic SF-36 measure, higher pulmonary symptom burden was strongly associated with poorer health related QoL ( r = .58, p < .001; higher scores indicating more impairment). In the subsample with SGRQ data, pulmonary symptom burden showed a very strong correlation with SGRQ Total ( r = .82, p < .001), indicating close agreement between transplant specific symptom reports and disease specific respiratory health status. The psychological distress index showed the expected pattern of correlations: higher distress was associated with lower EQ-5D Index Value ( r = -.57, p < .001), lower EQ-5D VAS ( r = -.37, p = .002), lower transplant specific general QoL ( r = -.28, p = .022), and worse SF-36 health-related QoL ( r = .57, p < .001). Table 2. Pearson correlations between pulmonary symptoms, psychological distress, and quality-of-life measures. Variable 1 2 3 4 5 6 7 8 9 1. LT-QoL Pulmonary Symptoms — .29* .39** .31* -.38** -.65*** -.43*** .58*** .82*** 2. HADS-Anxiety .29* — .62*** .87*** -.50*** -.39** -.23† .54*** .27 3. HADS-Depression .39** .62*** — .77*** -.39** -.38** -.31* .51*** .28† 4. Psychological distress index¹ .31* .87*** .77*** — -.57*** -.37** -.28* .57*** .23 5. EQ-5D Index Value -.38** -.50*** -.39** -.57*** — .58*** .28* -.64*** -.52** 6. EQ-5D VAS -.65*** -.39** -.38** -.37** .58*** — .31* -.66*** -.76*** 7. LT-QoL General QoL -.43*** -.23† -.31* -.28* .28* .31* — -.54*** -.43** 8. SF-36 overall QoL² .58*** .54*** .51*** .57*** -.64*** -.66*** -.54*** — .67*** 9. SGRQ Total .82*** .27 .28† .23 -.52** -.76*** -.43** .67*** — † p < .10; * p < .05; ** p < .01; *** p < .001. Notes. ¹ Psychological distress index is a standardized composite score derived from the HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress subscales (each subscale was z standardized and then averaged; higher scores indicate greater distress). 2 Values are Pearson correlation coefficients. Higher scores on LT-QoL Pulmonary Symptoms and SGRQ Total indicate worse respiratory status; higher scores on the EQ-5D and LT-QoL General QoL reflect better quality of life; higher SF-36 overall scores indicate more impairment. Hierarchical regression analyses To examine independent contributions of pulmonary symptoms and psychological distress, a series of hierarchical linear regression models was conducted with age, sex, and time since transplant entered as covariates in the first block, pulmonary symptom burden (LT-QoL Pulmonary Symptoms) in the second block, and the psychological distress index in the third block. Only the final models are summarized below (Table 3). Table 3. Final hierarchical regression models predicting quality of life outcomes. (a) EQ-5D Index Value Predictor B SE B β p Age (years) -0.001 0.001 -.13 .205 Sex (2 = female) -0.015 0.028 -.06 .595 Time since transplant (months) -0.0002 0.0004 -.04 .688 LT-QoL Pulmonary Symptoms -0.029 0.015 -.22 .055 Psychological distress index -0.075 0.015 -.52 < .001 Model statistics: R ² = .395, adjusted R ² = .346, F (5, 61) = 7.98, p < .001. (b) EQ-5D VAS Predictor B SE B β p Age (years) 0.008 0.141 .01 .957 Sex (2 = female) 6.60 3.96 .16 .101 Time since transplant (months) -0.071 0.063 -.11 .265 LT-QoL Pulmonary Symptoms -10.57 2.10 -.52 < .001 Psychological distress index -4.21 2.13 -.19 .053 Model statistics: R ² = .491, adjusted R ² = .449, F (5, 61) = 11.77, p < .001. (c) LT-QoL General Quality of Life Predictor B SE B β p Age (years) -0.015 0.009 -.20 .088 Sex (2 = female) -0.127 0.244 -.06 .604 Time since transplant (months) -0.001 0.004 -.03 .773 LT-QoL Pulmonary Symptoms -0.379 0.129 -.37 .005 Psychological distress index -0.213 0.131 -.19 .110 Model statistics: R ² = .253, adjusted R ² = .191, F (5, 61) = 4.13, p = .003. (d) SF-36 overall health related QoL (higher = worse) Predictor B SE B β p Age (years) 0.403 0.220 .17 .072 Sex (2 = female) -5.48 6.16 -.08 .377 Time since transplant (months) 0.053 0.097 .05 .585 LT-QoL Pulmonary Symptoms 13.39 3.28 .40 < .001 Psychological distress index 16.44 3.30 .46 < .001 Model statistics: R ² = .547, adjusted R ² = .509, F (5, 60) = 14.50, p < .001. EQ-5D Index Value For EQ-5D Index Value, the final model explained 39.5 percent of the variance ( R ² = .395, adjusted R ² = .346, F (5, 61) = 7.98, p < .001). In the fully adjusted model, higher pulmonary symptom burden showed a trend level association with lower EQ-5D Index Value ( B = -0.029, SE = 0.015, β = -.22, p = .055), whereas the psychological distress index emerged as a robust independent predictor ( B = -0.075, SE = 0.015, β = -.52, p < .001). Demographic and clinical covariates were not significant. EQ-5D VAS For the EQ-5D VAS, the final model accounted for 49.1 percent of the variance ( R ² = .491, adjusted R ² = .449, F (5, 61) = 11.77, p < .001). Greater pulmonary symptom burden was strongly associated with lower self-rated health ( B = -10.57, SE = 2.10, β = -.52, p < .001). The psychological distress index showed a weaker but borderline significant association ( B = -4.21, SE = 2.13, β = -.19, p = .053). None of the covariates reached statistical significance in the final model. For illustration, in this model a one-point increase in LT-QoL Pulmonary Symptoms on its 1 to 5 scale was associated with an approximately 11-point lower rating of current health on the 0 to 100 EQ-VAS, which is likely to be clinically meaningful at the individual patient level. Transplant-specific general QoL (LT-QoL General QoL) For the LT-QoL General QoL scale, the final model explained 25.3 percent of the variance ( R ² = .253, adjusted R ² = .191, F (5, 61) = 4.13, p = .003). Higher pulmonary symptom burden was significantly associated with lower transplant specific general QoL ( B = -0.379, SE = 0.129, β = -.37, p = .005). The psychological distress index showed a smaller and non-significant association ( B = -0.213, SE = 0.131, β = -.19, p = .110). Age, sex, and time since transplant were again not significant predictors. Generic health related QoL (SF-36) For the SF-36 overall health related QoL index (higher scores indicating worse status), the final model explained 54.7 percent of the variance ( R ² = .547, adjusted R ² = .509, F (5, 60) = 14.50, p < .001). Both pulmonary symptom burden and psychological distress were independently related to worse health related QoL. Pulmonary symptom burden had a large effect ( B = 13.39, SE = 3.28, β = .40, p < .001), and the psychological distress index contributed an additional, similarly strong effect ( B = 16.44, SE = 3.30, β = .46, p < .001). Covariates did not reach conventional significance. Mediation analyses To further clarify the interplay between pulmonary symptoms, psychological distress, and quality of life, structural equation models were estimated testing psychological distress as a mediator between pulmonary symptom burden and quality of life outcomes. In these models, pulmonary symptom burden was entered as a z-standardized LT-QoL Pulmonary Symptoms score, psychological distress was represented by the psychological distress index, and age, sex, and time since transplant were included as covariates. Parameter estimates are summarized in Table 4. Pulmonary symptom burden was positively associated with psychological distress (path: pulmonary symptom burden à psychological distress index, B = 0.259, SE = 0.113, z = 2.29, p = .022). In turn, higher psychological distress was strongly related to worse SF-36 health related QoL ( B = 16.45, SE = 3.13, z = 5.26, p < .001) and lower EQ-5D Index Value ( B = -0.075, SE = 0.022, z = -3.42, p < .001). For SF-36, there was a significant indirect effect of pulmonary symptom burden on health related QoL through psychological distress ( B = 4.26, SE = 1.87, z = 2.28, p = .023, 95 percent CI 0.93 to 9.84), in addition to a substantial direct effect ( B = 11.94, SE = 3.15, z = 3.79, p < .001). The total effect on SF-36 was large ( B = 16.20, SE = 3.14, z = 5.16, p < .001). For the EQ-5D Index Value, the total effect of pulmonary symptom burden was significant ( B = -0.045, SE = 0.014, z = -3.16, p = .002), and the indirect effect via psychological distress was also significant ( B = -0.019, SE = 0.009, z = -2.27, p = .023), whereas the direct effect in the mediation model did not reach conventional significance ( B = -0.026, SE = 0.015, p = .077). For the EQ-5D VAS and the LT-QoL General QoL scale, total effects of pulmonary symptom burden remained significant, but indirect effects via psychological distress were smaller and did not consistently reach statistical significance (Table 4). Table 4. Mediation of the association between pulmonary symptom burden and quality of life by psychological distress. Predictor: pulmonary symptom burden (standardized LT-QoL Pulmonary Symptoms score). Mediator: psychological distress index. Covariates: age, sex, time since transplant. Outcome Effect type b SE z p 95% CI lower 95% CI upper SF-36 overall quality of life Direct effect (controlling for psychological distress) 11.94 3.15 3.79 < .001 4.64 17.08 Indirect effect via psychological distress 4.26 1.87 2.28 .023 0.93 9.84 Total effect 16.20 3.14 5.16 < .001 9.36 21.77 EQ-5D Index Value Direct effect -0.03 0.02 -1.77 .077 -0.05 0.01 Indirect effect via psychological distress -0.02 0.01 -2.27 .023 -0.05 -0.00 Total effect -0.05 0.01 -3.16 .002 -0.09 -0.01 EQ-5D VAS Direct effect -9.41 2.46 -3.83 < .001 -13.39 -3.58 Indirect effect via psychological distress -1.09 0.68 -1.60 .109 -3.54 -0.05 Total effect -10.50 1.76 -5.97 < .001 -14.13 -5.58 LT-QOL General Quality of Life Direct effect -0.34 0.16 -2.12 .034 -0.65 -0.03 Indirect effect via psychological distress -0.06 0.04 -1.41 .158 -0.21 0.01 Total effect -0.39 0.11 -3.66 < .001 -0.65 -0.12 Notes. Pulmonary symptom burden (standardized) was obtained by z-standardizing the LT-QoL Pulmonary Symptoms subscale. The psychological distress index is a standardized composite score derived from HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress (each subscale z-standardized and averaged; higher scores indicate greater distress). All models adjust for age, sex, and time since transplant. Point estimates and z values are based on maximum likelihood estimation, whereas 95 percent confidence intervals are bias corrected bootstrap intervals as reported by JASP. In an additional parallel mediator model (not tabulated), the HADS-Anxiety and HADS-Depression subscales were entered separately as mediators. The pattern of results was broadly similar, with anxiety carrying most of the indirect effect, whereas the indirect paths via depression did not reach significance. Across all models, age, sex, and time since transplant were included as covariates and did not show consistent independent associations with quality of life outcomes. Discussion This study examined how transplant-specific pulmonary symptom burden and psychological distress are linked to multiple indicators of quality of life in long-term lung transplant recipients. Three main findings emerged. First, higher pulmonary symptom burden was consistently associated with poorer quality of life across generic, transplant specific, and respiratory specific measures. Second, a composite psychological distress index showed strong associations with quality of life, particularly with generic health-related quality of life. Third, psychological distress partially mediated the association between pulmonary symptom burden and selected quality of life outcomes, especially the EQ-5D Index Value and the SF-36 overall score. Pulmonary symptom burden and quality of life The observed levels of pulmonary symptoms were in the low to moderate range on average, yet even within this restricted spectrum symptom burden was robustly related to quality of life. Higher scores on the LT-QoL Pulmonary Symptoms scale were associated with worse EQ-5D outcomes, lower LT-QoL General Quality of Life, poorer SF-36 health status, and markedly worse disease specific respiratory status on the SGRQ. This pattern is consistent with prior work using the LT-QoL and other instruments, which has shown that residual dyspnea, cough, and respiratory limitations remain key determinants of health-related quality of life after lung transplantation, even among clinically stable survivors [1-4,7,10-12,25,26]. The very strong correlation between LT-QoL Pulmonary Symptoms and SGRQ Total supports the convergent validity of the LT-QoL pulmonary domain as a concise marker of respiratory health impairment [7-9, 25]. At the same time, the substantial associations with both EQ-5D indices and the SF-36 overall score underline that pulmonary symptoms are not confined to the respiratory domain but permeate patients’ broader perceptions of physical functioning, energy, and everyday life [1-4,6-8,10-12,25,26]. These findings are compatible with systematic reviews showing that, although lung transplantation improves health-related quality of life compared with pre-transplant status, many recipients continue to experience persistent limitations several years after surgery, with lung-related symptoms among the strongest correlates of impaired quality of life [1-5]. Psychological distress as a parallel and partial mediator The psychological distress index, integrating HADS Anxiety and Depression with the LT-QoL Anxiety/Depression and Health Distress subscales, showed good internal consistency (Cronbach’s alpha = .84 for standardized items) and behaved as a coherent marker of transdiagnostic emotional burden. As expected, higher distress was associated with lower EQ-5D Index Value and EQ-VAS scores, lower LT-QoL General Quality of Life, and worse SF-36 health-related quality of life. This aligns with prior work in lung and other solid organ transplant recipients, where elevated anxiety and depressive symptoms have been repeatedly linked to poorer quality of life and worse self-rated health [3,18-23,32]. Earlier studies have also documented that psychosocial vulnerability and distress are associated with more severe physical symptoms and physical impairment [19], more distressing treatment-related symptom experiences and lower adherence [20,23,24], higher rates of nonadherence across organ types [24], and in some cohorts, higher post-transplant mortality or worse composite outcomes [21,22,32]. A meta-analysis found no robust association between pretransplant anxiety/depression scores and posttransplant survival [32], which underlines that psychological distress may be more closely tied to functional outcomes and perceived health status than to hard survival endpoints. Our findings add to this literature by explicitly modeling psychological distress as a pathway linking pulmonary symptoms with quality of life rather than treating distress only as a parallel correlate. In the hierarchical regression models, pulmonary symptom burden and psychological distress made partly independent contributions to quality of life. For the SF-36 overall score, both predictors had large and comparable standardized effects, together explaining over half of the variance. For the EQ-5D Index Value, psychological distress emerged as the more robust independent predictor, whereas for the EQ-VAS and transplant-specific general quality of life the association with pulmonary symptoms was stronger and the additional contribution of psychological distress was weaker or borderline significant. This pattern suggests that patients’ cognitively integrated evaluations of health status, such as those captured by the EQ-5D Index Value and SF-36, may be particularly sensitive to emotional distress, whereas more immediate, global self-ratings and disease specific evaluations may be driven more directly by symptom burden. The mediation analyses further clarified these relationships. For the SF-36 overall score, psychological distress carried a significant part of the association between pulmonary symptom burden and health-related quality of life, while a substantial direct effect of pulmonary symptoms remained. This supports a dual pathway model, in which respiratory symptoms worsen quality of life both directly, through physical limitations and discomfort, and indirectly, by increasing emotional distress that in turn colors patients’ perceptions of their health. For the EQ-5D Index Value, the total effect of pulmonary symptom burden was partly explained by the indirect path through psychological distress, and the direct effect in the mediation model fell below conventional significance, consistent with partial mediation. In contrast, for the EQ-VAS and LT-QoL General Quality of Life scales, indirect effects via psychological distress were smaller and did not consistently reach significance, indicating that these outcomes are more tightly linked to symptom burden itself than to distress. The sensitivity analysis with HADS-Anxiety and HADS-Depression entered as parallel mediators suggests that anxiety may be particularly important in carrying the impact of pulmonary symptoms, whereas depression alone contributes less uniquely when shared variance is accounted for. This is clinically plausible, given that breathlessness and fluctuating respiratory status are prototypical triggers of health-related anxiety and hypervigilance in chronic lung disease [18,29]. An important conceptual consideration is the partial overlap between the psychological distress indicators and some of the quality of life outcomes. Both the EQ-5D Index Value and the SF-36 overall score include emotional components, and the LT-QoL Health Distress and Anxiety/Depression subscales capture related content. This conceptual proximity is likely to contribute to the strength of the associations between distress and generic QoL indices and may partly inflate estimates of the indirect effects. At the same time, the persistence of robust associations between pulmonary symptom burden and QoL after adjustment for distress, and the similar pattern of findings for more physically oriented outcomes such as the EQ-VAS, suggest that the interpretation of distress as a relevant parallel and partial mediator remains clinically meaningful. These findings also resonate with broader work on psychosocial risk and evaluation in transplantation, including structured tools such as the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) [28] and descriptive studies of psychosocial profiles among lung transplant candidates from the same center [25]. Together, these data underscore that psychosocial factors are integral to understanding post-transplant trajectories rather than an optional add-on [3,18-23,28,32]. Cluster-analytic work further suggests that a substantial subgroup of lung transplant recipients follows a trajectory of persistently high distress and impaired HRQoL, with little spontaneous improvement over time [1]. Clinical implications From a clinical perspective, the findings argue against a purely biomedical focus on lung function and rejection surveillance in long term follow-up. Even among relatively stable survivors several years after transplantation, modest elevations in pulmonary symptom burden and psychological distress were associated with meaningful decrements in quality of life. Systematic assessment of both domains is therefore warranted in routine care, using brief tools such as the LT-QoL pulmonary and emotional subscales together with generic quality of life measures (EQ-5D, SF-36) and brief anxiety/depression screens such as the HADS [7-12,15-17,33]. The partial mediation by psychological distress suggests that interventions targeting distress could attenuate some of the quality of life impact of pulmonary symptoms, even if residual symptoms cannot be fully eliminated. Integrated models of care that combine optimization of medical management with psychological support, such as cognitive behavioral strategies for health anxiety, coping with breathlessness, and adjustment to chronic graft-related limitations, may therefore be particularly beneficial. At the same time, the strong direct effects of pulmonary symptoms across outcomes highlight that optimizing pulmonary status, rehabilitation, and symptom management remains fundamental for preserving quality of life [1-4,6-8,10-12,18,25,26,30,31]. Emerging concepts of prehabilitation and ongoing rehabilitation in solid organ transplant candidates and recipients, which emphasize a combination of physical training, nutritional optimization and psychosocial interventions to enhance resilience before and after surgery, are consistent with this dual focus [30,31]. Narrative reviews and consensus statements suggest that such multimodal programs are feasible and may improve functional capacity and HRQoL, although high-quality randomized trials remain limited [30,31]. Strengths and limitations Key strengths of this study include the use of a disease-specific instrument tailored to lung transplant recipients, alongside multiple generic and respiratory specific quality of life measures [1-4,7-12,25,26,33], and the explicit modelling of psychological distress as a composite mediator. Using a composite index allowed us to capture shared variance across anxiety, depression and health-related distress without relying on arbitrary cut offs for any single scale [3,6,15-17,18-23,32,33]. The analytic strategy combined hierarchical regression with structural equation modelling, providing converging evidence on direct and indirect pathways. Several limitations should be acknowledged. First, the cross-sectional design precludes causal inference. Although the hypothesized direction from pulmonary symptoms to distress to quality of life is theoretically and clinically plausible, reverse and bidirectional influences are also likely [1-4,18-23,26,32,33]. For example, poorer perceived health and impaired HRQoL may increase psychological distress, which in turn may heighten symptom perception and symptom reporting. The mediation analyses therefore identify statistical indirect effects that are consistent with a dual pathway model, but they cannot establish temporal ordering or causal mediation. Second, there is conceptual overlap between the psychological distress index and some of the quality of life indices, particularly the EQ-5D Index and the SF-36 overall score, which include emotional components [10-12,15-17]. This overlap may inflate the strength of associations between distress and generic QoL. However, the robust associations observed between pulmonary symptoms and QoL after adjustment for distress, and the similar pattern of results for outcomes that are more strongly driven by physical status such as the EQ-VAS, argue against a purely artefactual explanation [1-4,7-12,18-23,25,26,33]. Third, the sample was recruited from a single transplant center and consisted of relatively long-term survivors, with a mean of nearly five years since transplantation. Patients with early post-transplant complications, those lost to follow-up and individuals with the most severe impairments are likely under represented. The recruitment strategy, which relied on attendees at routine outpatient visits and additional invitations by telephone or email, may also have preferentially included more engaged and better functioning patients [1-4,6,25,26,33]. As a result, the range of symptom burden and distress may be restricted, which would tend to underestimate true associations. Fourth, key variables were based on self-report questionnaires. Although these instruments have documented reliability and validity [7-12,15-17], responses may be influenced by current mood and reporting styles. The study did not include concurrent objective indicators such as lung function parameters, six-minute walk distance, chronic lung allograft dysfunction status or detailed comorbidity profiles, which would allow more fine-grained modelling of the links between physiological impairment, symptoms, distress and quality of life [1-4,6,18,21-23,25,26]. Future work should integrate patient reported outcomes with clinical and functional data to disentangle perceived from physiological impairment. Fifth, the psychological distress index aggregates heterogeneous emotional constructs. This approach improves reliability and parsimony, but may obscure potentially important differences between anxiety, depressive symptoms and health-related worry [3,6,18-23,32]. The parallel mediator analysis suggests that anxiety may be more closely tied to the impact of pulmonary symptoms than depression, but these findings require replication in larger samples. Sixth, the sample size for the structural equation models was modest relative to model complexity. Although we used bootstrap confidence intervals to increase robustness, estimates of indirect effects may still be unstable, and the mediation models should be viewed as exploratory. Finally, we examined multiple outcomes and conducted several related regression and mediation analyses without formal correction for multiple testing. In view of the exploratory nature of the study, we focused on the overall pattern of findings across outcomes and emphasized more robust and consistent effects, but some statistically significant results, particularly those with p values close to 0.05, should be interpreted with caution. Future directions Future research should build on these findings in several ways. Longitudinal studies with repeated assessments of symptoms, distress, and quality of life could clarify the temporal dynamics and test whether changes in distress mediate the impact of evolving pulmonary status on subsequent quality of life [1-4,18,21-23,26,32,33]. Incorporating objective clinical indicators and biomarkers would help disentangle perceived from physiological impairment and might identify subgroups in whom subjective distress is disproportionately high relative to clinical status [16,18,21-23,32]. Intervention studies are also needed to examine whether targeted psychological or integrated rehabilitation interventions can effectively reduce distress and improve quality of life among lung transplant recipients with elevated symptom burden, building on existing evidence for pulmonary rehabilitation and cognitive behavioral approaches in chronic lung disease and transplantation [3,18-23,29-31,32]. Finally, multi-center studies using harmonized lung-transplant-specific and generic instruments, including the LT-QoL, EQ-5D, and SF-36, could test the robustness of the present findings across healthcare systems and patient populations and inform the development of routine, low burden tools for monitoring both physical and psychological outcomes in long-term post-transplant care [1-4,7,10-12,26,33]. Abbreviations EQ-5D-5L - EuroQol 5-Dimension, 5-Level questionnaire EQ-5D Index Value - preference-based index derived from EQ-5D-5L health states EQ-VAS - EQ-5D Visual Analogue Scale HADS - Hospital Anxiety and Depression Scale HRQoL - Health-related quality of life LT-QoL - Lung Transplant Quality of Life questionnaire PROs - Patient-reported outcomes QoL - Quality of life SF-36 - 36-Item Short Form Health Survey SGRQ - St George’s Respiratory Questionnaire SIPAT - Stanford Integrated Psychosocial Assessment for Transplantation Declarations Ethics approval and consent to participate This retrospective cross-sectional study used anonymized data collected within a broader research project on lung transplant recipients, which was approved by the Independent Bioethics Committee for Scientific Research at the Medical University of Gdańsk, Poland. The present analyzes were based on questionnaire and clinical data collected during routine outpatient follow-up and did not modify patient management. All participants received information about the purpose and procedures of the broader research project and provided informed consent before completing the questionnaires (in written form during clinic visits or electronically or verbally for remote completion). Data were anonymized prior to analysis. All procedures were conducted in accordance with the ethical approval, institutional regulations, applicable data protection rules and the principles of the Declaration of Helsinki. All lung grafts in this cohort were procured and allocated via the national Polish transplantation system and the Department of Cardiac and Vascular Surgery, University Clinical Center in Gdańsk. Organs were obtained in accordance with Polish law and international ethical guidelines, including the Declaration of Istanbul. No organs or tissues were procured from prisoners at any stage of the transplantation process. Consent for publication Not applicable. The manuscript does not contain any individual person’s identifiable data in any form (including images, case descriptions or videos). Availability of data and materials The datasets generated and analyzed during the current study are not publicly available due to patient privacy and institutional data protection regulations but are available from the corresponding author on reasonable request. Competing interests The authors declare that they have no competing interests. Funding This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors. Authors’ contributions AS conceived and designed the study, coordinated data collection, performed the statistical analyses, interpreted the data and drafted the manuscript. SŻ contributed to patient recruitment, coordination of questionnaire completion during follow-up visits and acquisition of clinical data. WK contributed to the clinical interpretation of the findings and critically revised the manuscript for important intellectual content. JW provided clinical oversight of the lung transplant program and critically reviewed and approved the final version of the manuscript. All authors read and approved the final manuscript. Authors’ information Not applicable. References Seiler A, Klaghofer R, Ture M, Komossa K, Martin-Soelch C, Jenewein J. A systematic review of health-related quality of life and psychological outcomes after lung transplantation. J Heart Lung Transplant. 2016;35(2):195-202. Singer JP, Singer LG. Quality of life in lung transplantation. Semin Respir Crit Care Med. 2013;34(3):421-430. Singer JP, Katz PP, Soong A, Shrestha P, Huang D, Ho J, et al. Effect of Lung Transplantation on Health-Related Quality of Life in the Era of the Lung Allocation Score: A U.S. Prospective Cohort Study. Am J Transplant. 2017;17(5):1334-1345. Raguragavan A, Jayabalan D, Saxena A. Health-related Quality of Life Outcomes Following Single or Bilateral Lung Transplantation: A Systematic Review. Transplantation . 2023;107(4):838-848. Raguragavan A, Jayabalan D, Saxena A. Health-related quality of life following lung transplantation for cystic fibrosis: A systematic review. Clinics (Sao Paulo). 2023;78:100182. Guo S, Jia Y, Wang R, Sun J, Liu H. Psychological distress and self-psychological adjustment methods of lung transplant recipients: an overview of systematic reviews. BMC Psychol. 2025;13(1):884. Singer JP, Soong A, Chen J, Shrestha P, Zhuo H, Gao Y, et al. Development and Preliminary Validation of the Lung Transplant Quality of Life (LT-QOL) Survey. Am J Respir Crit Care Med. 2019;199(8):1008-1019. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321-1327. Kuźniar T, Patkowski J, Liebhart J, Wytrychowski K, Dobek R, Ślusarz R, et al. Validation of the Polish version of St. George’s respiratory questionnaire in patients with bronchial asthma. Pneumonol Alergol Pol. 1999;67(11-12):497-503. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473-483. Tylka J, Piotrowicz R. Kwestionariusz oceny jakości życia SF-36 - wersja polska [Quality of life questionnaire SF-36 - Polish version]. Kardiol Pol. 2009;67(10):1166-1169. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20(10):1727-1736. Golicki D, Jakubczyk M, Graczyk K, Niewada M. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe. Pharmacoeconomics . 2019;37(9):1165-1176. Golicki D. General population reference values for the EQ-5D-5L index in Poland: estimations using a Polish directly measured value set. Pol Arch Intern Med. 2021;131(5):484-486. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983;67(6):361-370. Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes. 2003;1:29. Mihalca AM, Pilecka W. The factorial structure and validity of the Hospital Anxiety and Depression Scale (HADS) in Polish adolescents. Psychiatr Pol. 2015;49(5):1071-1088. Dew MA, DiMartini AF, DeVito Dabbs AJ, Fox KR, Myaskovsky L, Posluszny DM, et al. Onset and risk factors for anxiety and depression during the first 2 years after lung transplantation. Gen Hosp Psychiatry. 2012;34(2):127-138. De Vito Dabbs A, Dew MA, Stilley CS, Manzetti J, Zullo T, McCurry KR, et al. Psychosocial vulnerability, physical symptoms and physical impairment after lung and heart-lung transplantation. J Heart Lung Transplant. 2003;22(11):1268-1275. Kugler C, Fischer S, Gottlieb J, Tegtbur U, Welte T, Goerler H, et al. Symptom experience after lung transplantation: impact on quality of life and adherence. Clin Transplant. 2007;21(5):590-596. Smith PJ, Blumenthal JA, Trulock EP, Freedland KE, Carney RM, Davis RD, et al. Psychosocial Predictors of Mortality Following Lung Transplantation. Am J Transplant. 2016;16(1):271-277. Smith PJ, Snyder LD, Palmer SM, Hoffman BM, Stonerock GL, Ingle KK, et al. Depression, social support, and clinical outcomes following lung transplantation: a single-center cohort study. Transpl Int. 2018;31(5):495-502. Wessels-Bakker MJ, van de Graaf EA, Kwakkel-van Erp JM, Heijerman HG, Cahn W, Schappin R. The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study. J Clin Nurs. 2022;31(5-6):716-725. Dew MA, DiMartini AF, De Vito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation . 2007;83(7):858-873. Karolak W, Stańska A, Wojarski J, Shinde R, Ciak E, Polishchuk A, et al. Demographic and Psychosocial Characteristics of Lung Transplant Candidates: Single-Center Analysis. Transplant Proc. 2022;54(4):1078-1081. Singh TP, Hsich E, Cherikh WS, Perch M, Hayes D Jr, Lewis A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation. J Heart Lung Transplant. 2025;44(12):1857-1873. Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34(1):1-15. Maldonado JR, Dubois HC, David EE, Sher Y, Lolak S, Dyal J, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. Psychosomatics . 2012;53(2):123-132. Yohannes AM, Junkes-Cunha M, Smith J, Vestbo J. Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review. J Am Med Dir Assoc. 2017;18(12):1096.e1-1096.e17. Quint EE, Ferreira M, van Munster BC, Nieuwenhuijs-Moeke G, Te Velde-Keyzer C, Bakker SJL, et al. Prehabilitation in Adult Solid Organ Transplant Candidates. Curr Transplant Rep. 2023;10(2):70-82. Annema C, De Smet S, Castle EM, Overloop Y, Klaase JM, Janaudis-Ferreira T, et al. European Society of Organ Transplantation (ESOT) Consensus Statement on Prehabilitation for Solid Organ Transplantation Candidates. Transpl Int. 2023;36:11564. Courtwright AM, Salomon S, Lehmann LS, Wolfe DJ, Goldberg HJ. The Effect of Pretransplant Depression and Anxiety on Survival Following Lung Transplant: A Meta-analysis. Psychosomatics . 2016;57(3):238-245. Stańska A, Karolak W, et al. Polish adaptation of the Lung Transplant Quality of Life (LT-QoL) questionnaire. Res Sq [Preprint] . 2024. Available from: https://www.researchsquare.com/article/rs-8129195/v1. Preprint, in review. Additional Declarations No competing interests reported. Cite Share Download PDF Status: Under Review Version 1 posted Reviews received at journal 12 Jan, 2026 Reviewers agreed at journal 09 Jan, 2026 Reviewers invited by journal 06 Jan, 2026 Editor assigned by journal 05 Jan, 2026 Editor invited by journal 12 Dec, 2025 Submission checks completed at journal 11 Dec, 2025 First submitted to journal 11 Dec, 2025 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8290982","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":571095915,"identity":"80fc0eae-7500-4b63-af6a-93720ef8bbd8","order_by":0,"name":"Stańska Aleksandra","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAAA8klEQVRIiWNgGAWjYPCCBAZ+MM0GxAeA+AFe1cwQLZINyFoSiNFicIBYLfz95w9+LviTJm98fo3phg9lDHJ8NxLYHuDTInEjmVl6ZluO4bYbb8xuzjjHYCx5I4HdAK/DbjAzSPM2VDBuu3HG7DZvG0PiBqAtEvi0yJ8/zPyb50+F/eYZQC1/2xjqCWoxOJDMJs3DlpO4gb/H7DZjG0OCASEthjeSzax529KSZ9xgK7vZc07CcOaZh+14/SJ3/uDj2zx/km37+w9vu/GjzEae73jysQcf8GhBAIhjJIAY6DziAP8BOJONSC2jYBSMglEwQgAA5dBT3DBz6UYAAAAASUVORK5CYII=","orcid":"","institution":"Medical University of Gdańsk","correspondingAuthor":true,"prefix":"","firstName":"Stańska","middleName":"","lastName":"Aleksandra","suffix":""},{"id":571095919,"identity":"7877cc03-b2c9-4327-a08f-592609d4ff41","order_by":1,"name":"Karolak Wojciech","email":"","orcid":"","institution":"Medical University of Gdańsk","correspondingAuthor":false,"prefix":"","firstName":"Karolak","middleName":"","lastName":"Wojciech","suffix":""},{"id":571095921,"identity":"7a26d19b-77f5-4446-a6b4-289c5ce02eb7","order_by":2,"name":"Żegleń Sławomir","email":"","orcid":"","institution":"Medical University of Gdańsk","correspondingAuthor":false,"prefix":"","firstName":"Żegleń","middleName":"","lastName":"Sławomir","suffix":""},{"id":571095922,"identity":"c79f71c9-cc5a-48c1-bcb2-53dc0688c14b","order_by":3,"name":"Wojarski Jacek","email":"","orcid":"","institution":"Medical University of Gdańsk","correspondingAuthor":false,"prefix":"","firstName":"Wojarski","middleName":"","lastName":"Jacek","suffix":""}],"badges":[],"createdAt":"2025-12-05 22:38:15","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8290982/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8290982/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":99813014,"identity":"9f188d28-afe6-4a87-8b14-24dda1db6c8c","added_by":"auto","created_at":"2026-01-08 14:38:22","extension":"docx","order_by":0,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":57675,"visible":true,"origin":"","legend":"","description":"","filename":"ArtykuLekiDepresja.docx","url":"https://assets-eu.researchsquare.com/files/rs-8290982/v1/8293399c5f1477b28613977a.docx"},{"id":99812774,"identity":"8eb0a6a6-fbac-41ce-af1e-749e8efde4e2","added_by":"auto","created_at":"2026-01-08 14:37:48","extension":"json","order_by":1,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":7115,"visible":true,"origin":"","legend":"","description":"","filename":"9a09fd9be9d14998868d7b9402c3135c.json","url":"https://assets-eu.researchsquare.com/files/rs-8290982/v1/505886e404a4ae75fa7d4338.json"},{"id":99812715,"identity":"d8e463d5-2b83-446c-943e-e9d6c3d8f78a","added_by":"auto","created_at":"2026-01-08 14:37:44","extension":"xml","order_by":2,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":171529,"visible":true,"origin":"","legend":"","description":"","filename":"9a09fd9be9d14998868d7b9402c3135c1enriched.xml","url":"https://assets-eu.researchsquare.com/files/rs-8290982/v1/a5564ad1e61d5d9daeed486a.xml"},{"id":99812494,"identity":"a0a3a3c3-e26d-4a9c-a637-123793f4e3dd","added_by":"auto","created_at":"2026-01-08 14:37:13","extension":"xml","order_by":3,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":169169,"visible":true,"origin":"","legend":"","description":"","filename":"9a09fd9be9d14998868d7b9402c3135c1structuring.xml","url":"https://assets-eu.researchsquare.com/files/rs-8290982/v1/60e87deb6f27beb2badde688.xml"},{"id":99812937,"identity":"69ba2a4f-6cf4-4e7e-a458-8822bfd26de3","added_by":"auto","created_at":"2026-01-08 14:38:13","extension":"html","order_by":4,"title":"","display":"","copyAsset":false,"role":"acdc-reference","size":186792,"visible":true,"origin":"","legend":"","description":"","filename":"earlyproof.html","url":"https://assets-eu.researchsquare.com/files/rs-8290982/v1/0fd21a5fbc80efbe861dc161.html"},{"id":99815579,"identity":"881a47b8-c8ba-4f2e-93e4-34d3217418f2","added_by":"auto","created_at":"2026-01-08 14:44:40","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":1247507,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8290982/v1/5b5f2f73-fb3f-4c5c-bd53-c854987453fd.pdf"}],"financialInterests":"No competing interests reported.","formattedTitle":"Pulmonary Symptoms and Psychological Distress as Correlates and Mediators of Quality of Life in Lung Transplant Recipients: A Cross- sectional Study","fulltext":[{"header":"Background","content":"\u003cp\u003eLung transplantation is a life-saving treatment for selected patients with end-stage respiratory disease, but long-term outcomes extend well beyond survival [1-3,26,27]. Recipients often live for many years with a complex burden of residual symptoms, treatment-related side effects, and psychosocial challenges, all of which can substantially affect health-related quality of life (HRQoL) [1-3]. Even in clinically stable patients with satisfactory graft function, limitations in physical capacity, persistent respiratory complaints, and chronic treatment burden may compromise daily functioning and subjective well-being [1-4]. As a result, international guidelines increasingly emphasize that routine follow-up after lung transplantation should include systematic assessment of patient-reported outcomes (PROs) such as symptoms and QoL, not only traditional clinical or physiological parameters [2,27]. Systematic reviews highlight substantial heterogeneity in concepts, instruments, and timing of HRQoL assessments after LTx, which complicates synthesis and benchmarking across studies [1,4,5].\u003c/p\u003e\n\u003cp\u003eRespiratory symptoms remain central to patients\u0026rsquo; post-transplant experience. Dyspnea, cough, and activity-related breathing discomfort may persist despite objectively improved lung function [1-4]. These symptoms can reflect chronic allograft dysfunction, comorbid disease, deconditioning, or treatment-related factors, and they are strongly linked to limitations in physical and social functioning [1-4]. Disease-specific instruments such as the Lung Transplant Quality of Life (LT-QoL) questionnaire and the St George\u0026rsquo;s Respiratory Questionnaire (SGRQ) were developed to capture such symptom burden and its impact on daily life in a more granular way than generic QoL measures [7-9]. However, less is known about how transplant-specific symptom burden relates simultaneously to generic QoL indices, disease-specific respiratory health status, and transplant-specific global QoL within the same cohort [1-4,7].\u003c/p\u003e\n\u003cp\u003ePsychological factors are another key component of post-transplant outcomes. Anxiety, depressive symptoms, and health-related worry are common after solid organ transplantation and have been consistently associated with poorer QoL, greater functional impairment, and worse perceived health status [3,6,18-23,32]. A recent overview of systematic reviews concluded that although a range of psychological interventions and self-adjustment strategies appear promising for lung transplant recipients, the overall methodological quality of the evidence remains modest [6].\u0026nbsp;In lung transplant recipients, psychological distress may arise from pre-transplant disease trajectories, prolonged hospitalization, fear of rejection or infection, and chronic treatment demands [3,6,18-23]. Screening tools such as the Hospital Anxiety and Depression Scale (HADS) are widely used to quantify anxiety and depressive symptoms in this population [15-17]. In addition, transplant-specific instruments like the LT-QoL include domains that capture health-related distress and emotional reactions to life after transplantation [7,33]. Despite this, the extent to which psychological distress helps to explain the impact of ongoing pulmonary symptom burden on QoL after lung transplantation is not fully understood [3,6,18-23,32].\u003c/p\u003e\n\u003cp\u003eMost previous studies have examined either the association between respiratory status and QoL or the association between psychological distress and QoL, often focusing on a single generic measure such as the SF-36 or EQ-5D [1-4,10-12,16,18,25,26]. Fewer analyses have integrated disease-specific symptom burden, transplant specific QoL, generic QoL, and psychological distress within a single analytic framework. In particular, it remains unclear whether the relationship between pulmonary symptoms and QoL is largely direct, or whether it is partly transmitted through heightened psychological distress [3,6,18-23,32]. Understanding these pathways is clinically important, because it may clarify whether interventions should focus primarily on symptom control, on psychological support, or on both in combination.\u003c/p\u003e\n\u003cp\u003eThe present study addresses this gap by examining how transplant-specific pulmonary symptom burden relates to multiple indicators of QoL in a cohort of adult lung transplant recipients, and by testing the mediating role of psychological distress. Using the Polish adaptation of the LT-QoL questionnaire together with the EQ-5D, SF-36, SGRQ, and HADS [7-9,10-12-14,15-17], we first describe the levels of symptom burden, psychological distress, and QoL in this sample and their bivariate associations. We then use hierarchical regression models to evaluate the independent contributions of pulmonary symptoms and psychological distress to generic and transplant specific QoL, controlling for age, sex, and time since transplantation. Finally, we apply mediation models to test whether psychological distress statistically mediates the association between pulmonary symptom burden and different QoL outcomes. These analyses are based on the same clinical cohort that was previously used for the linguistic and psychometric validation of the Polish LT-QoL [preprint, in review; 33], but the present work addresses distinct mechanistic questions about the interplay between symptoms, psychological distress, and QoL after lung transplantation.\u003c/p\u003e"},{"header":"Methods","content":"\u003cp\u003e\u003cstrong\u003eStudy design and participants\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis cross-sectional study was conducted in adult lung transplant recipients followed at the University Clinical Center in Gdańsk, Poland. The present analyses are based on the same clinical cohort that was used for the linguistic and psychometric validation of the Polish version of the LT-QoL questionnaire, reported in detail elsewhere [33]. The validation paper focused on translation procedures, factor structure and reliability of the LT-QoL. In contrast, the current study addressed distinct, pre-specified research questions about associations between pulmonary symptom burden, psychological distress and multiple indicators of quality of life. None of the regression or mediation models, hypotheses or outcome tables presented here were reported in the validation paper, so there is no overlap in the main analytic results.\u003c/p\u003e\n\u003cp\u003eEligible participants were adult lung transplant recipients who were attending routine outpatient follow-up during the recruitment period. Consecutive patients seen in the transplant clinic were invited to participate. In addition, patients without a scheduled visit in the near future were contacted by telephone or e-mail and could complete the questionnaires electronically or on paper and return them by post.\u003c/p\u003e\n\u003cp\u003eA total of 76 lung transplant recipients provided core sociodemographic and clinical data (age, sex, time since transplantation). Due to missing questionnaire responses, some analyses were conducted on slightly smaller subsamples; exact sample sizes for each instrument and analysis are reported in the tables. For the main analyses linking pulmonary symptoms, psychological distress, and quality of life, 67 participants had complete data for the LT-QoL Pulmonary Symptoms subscale, the psychological measures, and at least one quality of life outcome.\u003c/p\u003e\n\u003cp\u003eParticipation was voluntary. Patients provided informed consent prior to completing the questionnaires, either in written form (for paper questionnaires completed during clinic visits) or orally/electronically (for questionnaires completed remotely). The study was exploratory and non-interventional and relied exclusively on anonymized self-report data. The study was conducted in accordance with the principles of the Declaration of Helsinki.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMeasures\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll questionnaires used in this study were previously developed and validated instruments; no study-specific questionnaire was created for this project. The LT-QoL, EQ-5D-5L, SF-36, SGRQ and HADS were used in their validated Polish versions as referenced below.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSociodemographic and clinical variables\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eAge, sex, and time since lung transplantation (in months) were extracted from medical records and treated as covariates in all multivariable models.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eLung Transplant Quality of Life Questionnaire (LT-QoL)\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eDisease specific quality of life and symptom burden were assessed with the Polish version of the Lung Transplant Quality of Life (LT-QoL) questionnaire, originally developed by Singer and colleagues for lung transplant recipients [7,33]. The LT-QoL covers a broad range of domains relevant after lung transplantation, including symptom burden, functional limitations, emotional concerns, and overall quality of life [7,33]. It comprises first order subscales assessing specific domains such as Pulmonary Symptoms (Shortness of Breath, Cough), Gastrointestinal Symptoms, Neuromuscular Symptoms, Treatment Burden, Worry About Future Health, Cognitive Limitations, Sexual Problems, Anxiety and Depression, Health Distress, and General Quality of Life [7]. Several second order composite scales (for example Pulmonary Symptoms, Gastrointestinal Symptoms, Anxiety/Depression) can be derived by averaging conceptually related subscales.\u003c/p\u003e\n\u003cp\u003eIn the present study, two LT-QoL domains were of primary interest:\u003c/p\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003e\u003cstrong\u003eLT-QoL Pulmonary Symptoms\u003c/strong\u003e: a composite index capturing the severity of respiratory symptoms, calculated as the mean of the Shortness of Breath and Cough subscales. Scores range from 1 to 5, with higher scores indicating more severe pulmonary symptom burden.\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eLT-QoL General Quality of Life\u003c/strong\u003e: a single subscale assessing overall quality of life after lung transplantation. Unlike the symptom-oriented LT-QoL scales, higher scores on this subscale indicate better global quality of life (range 1 to 5).\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eIn addition, two emotion-related LT-QoL subscales:\u0026nbsp;\u003cstrong\u003eAnxiety/Depression\u003c/strong\u003e and\u0026nbsp;\u003cstrong\u003eHealth Distress\u003c/strong\u003e, were used as transplant-specific indicators of emotional burden and entered, together with HADS-Anxiety and HADS-Depression, into the composite psychological distress index (see Statistical analyses) [7,15-17,33].\u003c/p\u003e\n\u003cp\u003eAll LT-QoL items and subscales were scored according to the original authors\u0026rsquo; recommendations [7]. The linguistic adaptation and psychometric validation of the Polish LT-QoL are described in detail elsewhere; the present work uses the same scoring rules to ensure full comparability with prior studies [33].\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eHospital Anxiety and Depression Scale (HADS)\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003ePsychological symptoms were assessed with the Hospital Anxiety and Depression Scale (HADS), a widely used 14-item screening instrument designed for use in medical settings [15,16]. The HADS consists of two seven-item subscales measuring anxiety (HADS Anxiety) and depressive symptoms (HADS Depression). Items are rated on 4-point scales from 0 to 3, yielding subscale scores from 0 to 21, with higher scores indicating more severe symptomatology.\u003c/p\u003e\n\u003cp\u003eThe officially adapted Polish version of the HADS was used. Previous Polish validation studies have demonstrated satisfactory internal consistency, factorial validity, and convergent validity in medical and non-medical populations [17]. In the present study, HADS Anxiety and HADS Depression scores were calculated according to standard scoring rules, without any modifications.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003ePsychological distress index\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eTo capture overall psychological distress in a way that integrates symptom-specific and transplant-specific emotional burden, a composite psychological distress index was constructed. Four indicators were used:\u003c/p\u003e\n\u003cul type=\"disc\"\u003e\n \u003cli\u003eHADS Anxiety\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eHADS Depression\u0026nbsp;\u003c/li\u003e\n \u003cli\u003eLT-QoL Anxiety/Depression subscale\u003c/li\u003e\n \u003cli\u003eLT-QoL Health Distress subscale\u003c/li\u003e\n\u003c/ul\u003e\n\u003cp\u003eFirst, each of the four subscales was z standardized (mean 0, standard deviation 1). The psychological distress index was then calculated as the mean of these four z scores, with higher values indicating greater psychological distress.\u003c/p\u003e\n\u003cp\u003eInternal consistency of the four indicators used to derive the psychological distress index was good. In the current sample (\u003cem\u003eN\u003c/em\u003e = 67 with complete data), Cronbach\u0026rsquo;s alpha based on standardized subscale scores was 0.84, and inter-correlations among the indicators ranged from \u003cem\u003er\u0026nbsp;\u003c/em\u003e= .34 to \u003cem\u003er\u003c/em\u003e = .74, supporting the use of a single composite index.\u003c/p\u003e\n\u003cp\u003eConceptually, the composite index was intended to capture a transdiagnostic dimension of emotional burden that cuts across anxiety, depressive symptoms and transplant-specific health-related worry, rather than focusing on any single symptom cluster. Combining generic (HADS) and transplant specific (LT-QoL) indicators was expected to improve content validity and reduce measurement error associated with any one scale. In a sensitivity analysis we also examined models with HADS Anxiety and HADS Depression entered as separate mediators. Given the largely similar pattern of findings and the more parsimonious nature of the composite index, we retained the psychological distress index as the primary mediator in the main analyses.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEQ-5D-5L\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eGeneric health status was assessed using the EQ-5D 5L, developed by the EuroQol Group [12]. The EQ-5D-5L describes health across five dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), each rated on five levels of severity. These five responses form a five-digit health state profile. In addition, respondents rate their current overall health on a visual analogue scale (EQ-VAS) from 0 (worst imaginable health) to 100 (best imaginable health) [12].\u003c/p\u003e\n\u003cp\u003eFor the present study, EQ-5D-5L health states were converted into a single index value (EQ-5D Index Value) using the Polish value set based on time trade off valuations in a representative national sample [13,14]. Higher EQ-5D Index Value and EQ-VAS scores indicate better overall health status. The Polish adaptation and value set studies have shown good measurement properties and support use of EQ-5D-5L in clinical and population research in Poland.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSF-36 Health Survey\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eGlobal health-related quality of life was measured using the Polish version of the 36 Item Short Form Health Survey (SF-36) [10,11]. The SF-36 covers eight domains: physical functioning, role limitations due to physical health, bodily pain, general health perceptions, vitality, social functioning, role limitations due to emotional problems, and mental health [10]. Items are scored and transformed to 0-100 scales, where higher scores typically indicate better health.\u003c/p\u003e\n\u003cp\u003eFollowing the Polish scoring approach proposed by Tylka [11], items were first recoded using the Polish SF-36 key so that higher item scores reflect more negative evaluations or more frequent complaints. For each of the eight domains, item scores were summed and linearly transformed to a 0 to 100 scale, with higher domain scores indicating poorer health-related quality of life. To obtain a global index, we calculated the arithmetic mean of the eight domain scores, referred to in this study as the SF-36 overall health-related QoL score, where higher values indicate worse health status. This composite index was used as the primary SF-36 outcome in correlational, regression and mediation analyses.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eSt George\u0026rsquo;s Respiratory Questionnaire (SGRQ)\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eDisease-specific respiratory health-related quality of life was assessed with the St George\u0026rsquo;s Respiratory Questionnaire (SGRQ) [8,9]. The SGRQ yields three component scores (Symptoms, Activity, Impacts) and a Total score, each ranging from 0 to 100, where higher scores denote more severe respiratory health impairment [8].\u003c/p\u003e\n\u003cp\u003eThe officially adapted Polish version of the SGRQ was administered and scored according to the SGRQ manual. In the current study, the SGRQ Total score was used descriptively and in bivariate analyses as a disease specific comparator for LT-QoL Pulmonary Symptoms; due to the smaller subsample with available SGRQ data, it was not included in multivariable regression or mediation models.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eStatistical analyses\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAll analyses were conducted using IBM SPSS Statistics version 23 and JASP version 0.95.4. Statistical significance was set at \u003cem\u003ep\u003c/em\u003e \u0026lt; .05 (two tailed). Analyses were based on available cases. For descriptive statistics and correlations, pairwise non-missing data were used; for regression and mediation models, listwise deletion was applied for the variables in each model. Exact sample sizes are reported in the tables.\u003c/p\u003e\n\u003cp\u003eFirst, descriptive statistics were calculated for all variables, including means, standard deviations, and observed ranges for continuous variables and counts and percentages for categorical variables. Internal consistency of the indicators that formed the psychological distress index (HADS Anxiety, HADS Depression, LT-QoL Anxiety/Depression, LT-QoL Health Distress) was evaluated using Cronbach\u0026rsquo;s alpha based on standardized scores.\u003c/p\u003e\n\u003cp\u003ePearson correlation coefficients were computed to examine bivariate associations between pulmonary symptom burden (LT-QoL Pulmonary Symptoms), HADS Anxiety, HADS Depression, the psychological distress index, generic and transplant specific quality of life measures (EQ-5D Index Value, EQ-VAS, LT-QoL General Quality of Life, SF-36 overall score), and SGRQ Total.\u003c/p\u003e\n\u003cp\u003eTo assess the independent contributions of pulmonary symptoms and psychological distress to quality of life, hierarchical linear regression analyses were performed for four outcomes: EQ-5D Index Value, EQ-VAS, LT-QoL General Quality of Life, and the SF-36 overall score. For each outcome, age, sex, and time since transplantation (months) were entered as covariates in block 1. LT-QoL Pulmonary Symptoms (pulmonary symptom burden) was entered in block 2, and the psychological distress index was added in block 3. For each final model, unstandardized regression coefficients (B), standard errors, standardized coefficients (\u0026beta;), p values, and model fit indices (R\u0026sup2;, adjusted R\u0026sup2;, F, p) were reported.\u003c/p\u003e\n\u003cp\u003eTo further elucidate the interplay between pulmonary symptoms, psychological distress, and quality of life, mediation models were estimated using structural equation modeling in JASP (version 0.95.4). In these models, pulmonary symptom burden was represented by the LT-QoL Pulmonary Symptoms (predictor), psychological distress by the psychological distress index (mediator), and quality of life by each of the four outcomes (EQ-5D Index Value, EQ-VAS, LT-QoL General Quality of Life, and the SF-36 overall score) in turn. Age, sex, and time since transplantation were included as covariates and were allowed to predict the predictor, the mediator, and each outcome.\u003c/p\u003e\n\u003cp\u003eParameters were estimated using maximum likelihood. For each path, we report maximum-likelihood point estimates, standard errors, z values and p values, and 95% bias-corrected bootstrap confidence intervals based on 5000 resamples. For indirect effects, statistical significance was evaluated primarily based on the bootstrap confidence intervals; indirect effects were considered statistically significant when the 95% confidence interval did not include zero.\u003c/p\u003e\n\u003cp\u003eAs a sensitivity analysis, an additional parallel mediator model was estimated in which the HADS Anxiety and HADS Depression subscale scores were entered as separate mediators between pulmonary symptom burden and quality of life outcomes. This model was used to explore whether anxiety and depressive symptoms contributed differentially to the associations of pulmonary symptom burden with quality of life. Given the largely similar pattern of findings and the more parsimonious nature of the composite psychological distress index, detailed results of the parallel mediator model are summarized narratively rather than tabulated.\u003c/p\u003e\n\u003cp\u003eGiven the exploratory nature of the study and the modest sample size, we did not apply formal corrections for multiple testing. Instead, we interpreted patterns of associations across outcomes and models rather than relying on isolated p values close to the 0.05 threshold. The mediation models were estimated in cross-sectional data and are therefore intended to identify statistical indirect effects that are consistent with theoretically plausible pathways, rather than to establish causal mediation or temporal ordering.\u003c/p\u003e"},{"header":"Results","content":"\u003cp\u003e\u003cstrong\u003eSample characteristics\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe final sample comprised 76 lung transplant recipients (55 men, 72.4%, and 21 women, 27.6%). The mean age was \u003cem\u003eM\u003c/em\u003e = 57.57 years (\u003cem\u003eSD\u003c/em\u003e = 12.92, range 25 to 77), and the mean time since lung transplantation was \u003cem\u003eM\u003c/em\u003e = 56.59 months (\u003cem\u003eSD\u003c/em\u003e = 30.35, range 33 to 197; Table 1).\u003c/p\u003e\n\u003cp\u003eOn the transplant specific LT-QoL Pulmonary Symptoms subscale (higher scores indicating more severe respiratory symptoms), the mean score was low to moderate (\u003cem\u003eM\u003c/em\u003e = 2.05, \u003cem\u003eSD\u003c/em\u003e = 0.89, range 1.00 to 5.00). The psychological distress index, a standardized composite of HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress subscales (each z-standardized and then averaged), was centered around zero (\u003cem\u003eM\u003c/em\u003e = 0.00, \u003cem\u003eSD\u003c/em\u003e = 0.82, range -1.00 to 2.17).\u0026nbsp;Generic health-related quality of life was relatively preserved: mean EQ-5D Index Value was \u003cem\u003eM\u003c/em\u003e = 0.92 (\u003cem\u003eSD\u003c/em\u003e = 0.12), and mean EQ-5D VAS was \u003cem\u003eM\u003c/em\u003e = 75.21 (\u003cem\u003eSD\u003c/em\u003e = 18.17). Transplant-specific general quality of life (LT-QoL General QoL) was also high (\u003cem\u003eM\u003c/em\u003e = 4.18, \u003cem\u003eSD\u003c/em\u003e = 0.92).\u003c/p\u003e\n\u003cp\u003eHigher scores on the SF-36 overall health-related QoL index and on the SGRQ Total score reflected worse health status; mean SF-36 overall score was \u003cem\u003eM\u003c/em\u003e = 54.17 (\u003cem\u003eSD\u003c/em\u003e = 29.82) and mean SGRQ Total score was \u003cem\u003eM\u003c/em\u003e = 10.14 (\u003cem\u003eSD\u003c/em\u003e = 6.91, \u003cem\u003eN\u003c/em\u003e = 37). Sample sizes varied across measures due to missing questionnaire data; exact n values for each variable are reported in Table 1.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 1.\u0026nbsp;\u003c/strong\u003eSample characteristics and descriptive statistics.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003en\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMinimum\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eMaximum\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eM\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eSD\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e25.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e77.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e57.57\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e12.92\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eTime since lung transplantation (months)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e33.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e197.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e56.59\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e30.35\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eLT-QoL Pulmonary Symptoms (1 to 5; higher = more symptoms)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e5.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e2.05\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e0.89\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003ePsychological distress index\u0026sup1;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e2.17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e0.00\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e0.82\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eEQ-5D Index Value (0 to 1; higher = better)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.38\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e0.92\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e0.12\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eEQ-5D VAS (0 to 100; higher = better)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e15.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e100.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e75.21\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e18.17\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eLT-QoL General Quality of Life (1 to 5; higher = better)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e67\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e1.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e5.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e4.18\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e0.92\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eSF-36 overall health related QoL\u0026sup2;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e7.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e125.00\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e54.17\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e29.82\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 62px;\"\u003e\n \u003cp\u003eSGRQ Total (0 to 100; higher = worse)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e0.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e29.57\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cem\u003e10.14\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cem\u003e6.91\u003c/em\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026nbsp;\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eCategorical variable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eCategory\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003en\u003c/em\u003e\u003c/strong\u003e\u003cstrong\u003e\u0026nbsp;(%)\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eSex\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eMale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e55 (72.4)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eFemale\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e21 (27.6)\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eNotes.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026sup1; Psychological distress index is a standardized composite score derived from HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress (each subscale was z-standardized and then averaged; higher scores indicate greater distress).\u003c/p\u003e\n\u003cp\u003e\u0026sup2; Higher SF-36 overall scores reflect worse health related quality of life.\u003c/p\u003e\n\u003cp\u003ePrimary indications for lung transplantation in this clinical cohort were similar to those reported in our previous LT-QoL validation study from the same center [33]. In that validation sample, the most frequent indications were chronic obstructive pulmonary disease (27 patients, 38.6%) and idiopathic pulmonary fibrosis (15, 21.4%), followed by allergic alveolitis (6, 8.6%), pulmonary arterial hypertension (6, 8.6%), post-COVID-19 respiratory failure (5, 7.1%), sarcoidosis (3, 4.3%), systemic sclerosis (2, 2.9%), rheumatoid arthritis (2, 2.9%), histiocytosis (1, 1.4%), silicosis (1, 1.4%), and other rare interstitial or occupational lung diseases (2, 2.9%). The present analytic sample is nested within this clinical cohort and therefore reflects a comparable diagnostic spectrum.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eBivariate associations\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePearson correlations are presented in Table 2. Higher pulmonary symptom burden was consistently associated with more psychological symptoms and poorer quality of life.\u003c/p\u003e\n\u003cp\u003ePulmonary symptom burden correlated positively with HADS-Anxiety (\u003cem\u003er\u003c/em\u003e = .29, \u003cem\u003ep\u003c/em\u003e = .018) and HADS-Depression (\u003cem\u003er\u003c/em\u003e = .39, \u003cem\u003ep\u003c/em\u003e = .001), as well as with the psychological distress index (\u003cem\u003er\u003c/em\u003e = .31, \u003cem\u003ep\u003c/em\u003e = .011). Greater symptom burden was related to worse generic QoL on both EQ-5D measures (EQ-5D Index Value: \u003cem\u003er\u003c/em\u003e = -.38, \u003cem\u003ep\u003c/em\u003e = .001; EQ-5D VAS: \u003cem\u003er\u003c/em\u003e = -.65, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001) and to lower transplant specific general QoL (\u003cem\u003er\u003c/em\u003e = -.43, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001).\u003c/p\u003e\n\u003cp\u003eRegarding the generic SF-36 measure, higher pulmonary symptom burden was strongly associated with poorer health related QoL (\u003cem\u003er\u003c/em\u003e = .58, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001; higher scores indicating more impairment). In the subsample with SGRQ data, pulmonary symptom burden showed a very strong correlation with SGRQ Total (\u003cem\u003er\u003c/em\u003e = .82, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001), indicating close agreement between transplant specific symptom reports and disease specific respiratory health status.\u003c/p\u003e\n\u003cp\u003eThe psychological distress index showed the expected pattern of correlations: higher distress was associated with lower EQ-5D Index Value (\u003cem\u003er\u003c/em\u003e = -.57, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001), lower EQ-5D VAS (\u003cem\u003er\u003c/em\u003e = -.37, \u003cem\u003ep\u003c/em\u003e = .002), lower transplant specific general QoL (\u003cem\u003er\u003c/em\u003e = -.28, \u003cem\u003ep\u003c/em\u003e = .022), and worse SF-36 health-related QoL (\u003cem\u003er\u003c/em\u003e = .57, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 2.\u0026nbsp;\u003c/strong\u003ePearson correlations between pulmonary symptoms, psychological distress, and quality-of-life measures.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\" width=\"100%\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e\u003cstrong\u003eVariable\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e1\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e2\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e3\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e4\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e5\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e6\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e7\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e8\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u003cstrong\u003e9\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e1. LT-QoL Pulmonary Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.29*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e.39**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.31*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.38**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.65***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.43***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.58***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.82***\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e2. HADS-Anxiety\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.29*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e.62***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.87***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.50***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.39**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.23\u0026dagger;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.54***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.27\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e3. HADS-Depression\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.39**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.62***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.77***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.39**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.38**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.31*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.51***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.28\u0026dagger;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e4. Psychological distress index\u0026sup1;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.31*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.87***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e.77***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.57***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.37**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.28*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.57***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.23\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e5. EQ-5D Index Value\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.38**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.50***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e-.39**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.57***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.58***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.28*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.64***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.52**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e6. EQ-5D VAS\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.65***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.39**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e-.38**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.37**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.58***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.31*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.66***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.76***\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e7. LT-QoL General QoL\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.43***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.23\u0026dagger;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e-.31*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.28*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.28*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.31*\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.54***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.43**\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e8. SF-36 overall QoL\u0026sup2;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.58***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.54***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e.51***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.57***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.64***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.66***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.54***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.67***\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd style=\"width: 31px;\"\u003e\n \u003cp\u003e9. SGRQ Total\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.82***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 6px;\"\u003e\n \u003cp\u003e.28\u0026dagger;\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.23\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.52**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.76***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e-.43**\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e.67***\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd style=\"width: 7px;\"\u003e\n \u003cp\u003e\u0026mdash;\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u0026dagger; \u003cem\u003ep\u003c/em\u003e \u0026lt; .10; *\u003cem\u003ep\u003c/em\u003e \u0026lt; .05; ** \u003cem\u003ep\u003c/em\u003e \u0026lt; .01; *** \u003cem\u003ep\u003c/em\u003e \u0026lt; .001.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eNotes.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003e\u0026sup1; Psychological distress index is a standardized composite score derived from the HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress subscales (each subscale was z standardized and then averaged; higher scores indicate greater distress).\u003c/p\u003e\n\u003cp\u003e\u003csup\u003e2\u0026nbsp;\u003c/sup\u003eValues are Pearson correlation coefficients. Higher scores on LT-QoL Pulmonary Symptoms and SGRQ Total indicate worse respiratory status; higher scores on the EQ-5D and LT-QoL General QoL reflect better quality of life; higher SF-36 overall scores indicate more impairment.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eHierarchical regression analyses\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo examine independent contributions of pulmonary symptoms and psychological distress, a series of hierarchical linear regression models was conducted with age, sex, and time since transplant entered as covariates in the first block, pulmonary symptom burden (LT-QoL Pulmonary Symptoms) in the second block, and the psychological distress index in the third block. Only the final models are summarized below (Table 3).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 3.\u0026nbsp;\u003c/strong\u003eFinal hierarchical regression models predicting quality of life outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(a) EQ-5D Index Value\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003ePredictor\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eB\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eSE B\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003e\u0026beta;\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.205\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eSex (2 = female)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.028\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.595\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eTime since transplant (months)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.0002\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.0004\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.688\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eLT-QoL Pulmonary Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.029\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.22\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.055\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003ePsychological distress index\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.075\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eModel statistics: \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .395, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .346, \u003cem\u003eF\u003c/em\u003e(5, 61) = 7.98, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(b) EQ-5D VAS\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003ePredictor\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eB\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eSE B\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003e\u0026beta;\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.008\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.141\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.957\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eSex (2 = female)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e6.60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3.96\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.101\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eTime since transplant (months)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.071\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.063\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.265\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eLT-QoL Pulmonary Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-10.57\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2.10\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.52\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003ePsychological distress index\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-4.21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.053\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eModel statistics: \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .491, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .449, \u003cem\u003eF\u003c/em\u003e(5, 61) = 11.77, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(c) LT-QoL General Quality of Life\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003ePredictor\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eB\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eSE B\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003e\u0026beta;\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.015\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.009\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.088\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eSex (2 = female)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.127\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.244\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.604\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eTime since transplant (months)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.004\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.773\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eLT-QoL Pulmonary Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.379\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.129\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.37\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.005\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003ePsychological distress index\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.213\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.131\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.19\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.110\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eModel statistics: \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .253, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .191, \u003cem\u003eF\u003c/em\u003e(5, 61) = 4.13, \u003cem\u003ep\u003c/em\u003e = .003.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003e(d) SF-36 overall health related QoL (higher = worse)\u003c/strong\u003e\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003cthead\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003ePredictor\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eB\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eSE B\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003e\u0026beta;\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/thead\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eAge (years)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.403\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.220\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.17\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.072\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eSex (2 = female)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-5.48\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e6.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-.08\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.377\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eTime since transplant (months)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.053\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.097\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.585\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003eLT-QoL Pulmonary Symptoms\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e13.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.40\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003ePsychological distress index\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e16.44\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3.30\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003eModel statistics: \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .547, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .509, \u003cem\u003eF\u003c/em\u003e(5, 60) = 14.50, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEQ-5D Index Value\u0026nbsp;\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eFor EQ-5D Index Value, the final model explained 39.5 percent of the variance (\u003cem\u003eR\u003c/em\u003e\u0026sup2; = .395, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .346, \u003cem\u003eF\u003c/em\u003e(5, 61) = 7.98, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). In the fully adjusted model, higher pulmonary symptom burden showed a trend level association with lower EQ-5D Index Value (\u003cem\u003eB\u003c/em\u003e = -0.029, \u003cem\u003eSE\u003c/em\u003e = 0.015, \u003cem\u003e\u0026beta;\u003c/em\u003e = -.22, \u003cem\u003ep\u003c/em\u003e = .055), whereas the psychological distress index emerged as a robust independent predictor (\u003cem\u003eB\u003c/em\u003e = -0.075, \u003cem\u003eSE\u003c/em\u003e = 0.015, \u003cem\u003e\u0026beta;\u003c/em\u003e = -.52, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). Demographic and clinical covariates were not significant.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eEQ-5D VAS\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eFor the EQ-5D VAS, the final model accounted for 49.1 percent of the variance (\u003cem\u003eR\u003c/em\u003e\u0026sup2; = .491, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .449, \u003cem\u003eF\u003c/em\u003e(5, 61) = 11.77, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). Greater pulmonary symptom burden was strongly associated with lower self-rated health (\u003cem\u003eB\u003c/em\u003e = -10.57, \u003cem\u003eSE\u003c/em\u003e = 2.10, \u003cem\u003e\u0026beta;\u003c/em\u003e = -.52, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). The psychological distress index showed a weaker but borderline significant association (\u003cem\u003eB\u003c/em\u003e = -4.21, \u003cem\u003eSE\u003c/em\u003e = 2.13, \u003cem\u003e\u0026beta;\u003c/em\u003e = -.19, \u003cem\u003ep\u003c/em\u003e = .053). None of the covariates reached statistical significance in the final model.\u0026nbsp;For illustration, in this model a one-point increase in LT-QoL Pulmonary Symptoms on its 1 to 5 scale was associated with an approximately 11-point lower rating of current health on the 0 to 100 EQ-VAS, which is likely to be clinically meaningful at the individual patient level.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eTransplant-specific general QoL (LT-QoL General QoL)\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eFor the LT-QoL General QoL scale, the final model explained 25.3 percent of the variance (\u003cem\u003eR\u003c/em\u003e\u0026sup2; = .253, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .191, \u003cem\u003eF\u003c/em\u003e(5, 61) = 4.13, \u003cem\u003ep\u003c/em\u003e = .003). Higher pulmonary symptom burden was significantly associated with lower transplant specific general QoL (\u003cem\u003eB\u003c/em\u003e = -0.379, \u003cem\u003eSE\u003c/em\u003e = 0.129, \u003cem\u003e\u0026beta;\u003c/em\u003e = -.37, \u003cem\u003ep\u003c/em\u003e = .005). The psychological distress index showed a smaller and non-significant association (\u003cem\u003eB\u003c/em\u003e = -0.213, \u003cem\u003eSE\u003c/em\u003e = 0.131, \u003cem\u003e\u0026beta;\u003c/em\u003e = -.19, \u003cem\u003ep\u003c/em\u003e = .110). Age, sex, and time since transplant were again not significant predictors.\u003c/p\u003e\n\u003cp\u003e\u003cem\u003eGeneric health related QoL (SF-36)\u003c/em\u003e\u003c/p\u003e\n\u003cp\u003eFor the SF-36 overall health related QoL index (higher scores indicating worse status), the final model explained 54.7 percent of the variance (\u003cem\u003eR\u003c/em\u003e\u0026sup2; = .547, adjusted \u003cem\u003eR\u003c/em\u003e\u0026sup2; = .509, \u003cem\u003eF\u003c/em\u003e(5, 60) = 14.50, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). Both pulmonary symptom burden and psychological distress were independently related to worse health related QoL. Pulmonary symptom burden had a large effect (\u003cem\u003eB\u003c/em\u003e = 13.39, \u003cem\u003eSE\u003c/em\u003e = 3.28, \u003cem\u003e\u0026beta;\u003c/em\u003e = .40, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001), and the psychological distress index contributed an additional, similarly strong effect (\u003cem\u003eB\u003c/em\u003e = 16.44, \u003cem\u003eSE\u003c/em\u003e = 3.30, \u003cem\u003e\u0026beta;\u003c/em\u003e = .46, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). Covariates did not reach conventional significance.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMediation analyses\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eTo further clarify the interplay between pulmonary symptoms, psychological distress, and quality of life, structural equation models were estimated testing psychological distress as a mediator between pulmonary symptom burden and quality of life outcomes.\u0026nbsp;In these models, pulmonary symptom burden was entered as a z-standardized LT-QoL Pulmonary Symptoms score, psychological distress was represented by the psychological distress index, and age, sex, and time since transplant were included as covariates.\u0026nbsp;Parameter estimates are summarized in Table 4.\u003c/p\u003e\n\u003cp\u003ePulmonary symptom burden was positively associated with psychological distress (path: pulmonary symptom burden\u0026nbsp;\u0026agrave;\u0026nbsp;psychological distress index, \u003cem\u003eB\u003c/em\u003e = 0.259, \u003cem\u003eSE\u003c/em\u003e = 0.113, \u003cem\u003ez\u003c/em\u003e = 2.29, \u003cem\u003ep\u003c/em\u003e = .022). In turn, higher psychological distress was strongly related to worse SF-36 health related QoL (\u003cem\u003eB\u003c/em\u003e = 16.45, \u003cem\u003eSE\u003c/em\u003e = 3.13, \u003cem\u003ez\u003c/em\u003e = 5.26, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001) and lower EQ-5D Index Value (\u003cem\u003eB\u003c/em\u003e = -0.075, \u003cem\u003eSE\u003c/em\u003e = 0.022, \u003cem\u003ez\u003c/em\u003e = -3.42, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001).\u003c/p\u003e\n\u003cp\u003eFor SF-36, there was a significant indirect effect of pulmonary symptom burden on health related QoL through psychological distress (\u003cem\u003eB\u003c/em\u003e = 4.26, \u003cem\u003eSE\u003c/em\u003e = 1.87, \u003cem\u003ez\u003c/em\u003e = 2.28, \u003cem\u003ep\u003c/em\u003e = .023, 95 percent CI 0.93 to 9.84), in addition to a substantial direct effect (\u003cem\u003eB\u003c/em\u003e = 11.94, \u003cem\u003eSE\u003c/em\u003e = 3.15, \u003cem\u003ez\u003c/em\u003e = 3.79, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001). The total effect on SF-36 was large (\u003cem\u003eB\u003c/em\u003e = 16.20, \u003cem\u003eSE\u003c/em\u003e = 3.14, \u003cem\u003ez\u003c/em\u003e = 5.16, \u003cem\u003ep\u003c/em\u003e \u0026lt; .001).\u003c/p\u003e\n\u003cp\u003eFor the EQ-5D Index Value, the total effect of pulmonary symptom burden was significant (\u003cem\u003eB\u003c/em\u003e = -0.045, \u003cem\u003eSE\u003c/em\u003e = 0.014, \u003cem\u003ez\u003c/em\u003e = -3.16, \u003cem\u003ep\u003c/em\u003e = .002), and the indirect effect via psychological distress was also significant (\u003cem\u003eB\u003c/em\u003e = -0.019, \u003cem\u003eSE\u003c/em\u003e = 0.009, \u003cem\u003ez\u003c/em\u003e = -2.27, \u003cem\u003ep\u003c/em\u003e = .023), whereas the direct effect in the mediation model did not reach conventional significance (\u003cem\u003eB\u003c/em\u003e = -0.026, \u003cem\u003eSE\u003c/em\u003e = 0.015, \u003cem\u003ep\u003c/em\u003e = .077).\u003c/p\u003e\n\u003cp\u003eFor the EQ-5D VAS and the LT-QoL General QoL scale, total effects of pulmonary symptom burden remained significant, but indirect effects via psychological distress were smaller and did not consistently reach statistical significance (Table 4).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eTable 4.\u0026nbsp;\u003c/strong\u003eMediation of the association between pulmonary symptom burden and quality of life by psychological distress.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003ePredictor:\u003c/strong\u003e pulmonary symptom burden (standardized LT-QoL Pulmonary Symptoms score). Mediator: psychological distress index. \u003cstrong\u003eCovariates:\u0026nbsp;\u003c/strong\u003eage, sex, time since transplant.\u003c/p\u003e\n\u003ctable border=\"0\" cellspacing=\"3\" cellpadding=\"0\"\u003e\n \u003ctbody\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eOutcome\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eEffect type\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eb\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003eSE\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ez\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e\u003cem\u003ep\u003c/em\u003e\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e95% CI lower\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003e95% CI upper\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eSF-36 overall quality of life\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eDirect effect (controlling for psychological distress)\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e11.94\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3.15\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3.79\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e4.64\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e17.08\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIndirect effect via psychological distress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e4.26\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e1.87\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2.28\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.93\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e9.84\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eTotal effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e16.20\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e3.14\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e5.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e9.36\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e21.77\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eEQ-5D Index Value\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eDirect effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-1.77\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.077\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIndirect effect via psychological distress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.02\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-2.27\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.023\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.00\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eTotal effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-3.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.002\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eEQ-5D VAS\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eDirect effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-9.41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e2.46\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-3.83\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-13.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-3.58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIndirect effect via psychological distress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-1.09\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.68\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-1.60\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.109\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-3.54\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.05\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eTotal effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-10.50\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e1.76\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-5.97\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-14.13\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-5.58\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\n \u003cp\u003e\u003cstrong\u003eLT-QOL General Quality of Life\u003c/strong\u003e\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eDirect effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.34\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.16\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-2.12\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.034\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.03\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eIndirect effect via psychological distress\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.06\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.04\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-1.41\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e.158\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.21\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.01\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003ctr\u003e\n \u003ctd\u003e\u003cbr\u003e\u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003eTotal effect\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.39\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e0.11\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-3.66\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e\u0026lt; .001\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.65\u003c/p\u003e\n \u003c/td\u003e\n \u003ctd\u003e\n \u003cp\u003e-0.12\u003c/p\u003e\n \u003c/td\u003e\n \u003c/tr\u003e\n \u003c/tbody\u003e\n\u003c/table\u003e\n\u003cp\u003e\u003cstrong\u003eNotes.\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003ePulmonary symptom burden (standardized) was obtained by z-standardizing the LT-QoL Pulmonary Symptoms subscale. The psychological distress index is a standardized composite score derived from HADS-Anxiety, HADS-Depression, LT-QoL Anxiety/Depression, and LT-QoL Health Distress (each subscale z-standardized and averaged; higher scores indicate greater distress). All models adjust for age, sex, and time since transplant. Point estimates and z values are based on maximum likelihood estimation, whereas 95 percent confidence intervals are bias corrected bootstrap intervals as reported by JASP.\u003c/p\u003e\n\u003cp\u003eIn an additional parallel mediator model (not tabulated), the HADS-Anxiety and HADS-Depression subscales were entered separately as mediators. The pattern of results was broadly similar, with anxiety carrying most of the indirect effect, whereas the indirect paths via depression did not reach significance.\u003c/p\u003e\n\u003cp\u003eAcross all models, age, sex, and time since transplant were included as covariates and did not show consistent independent associations with quality of life outcomes.\u003c/p\u003e"},{"header":"Discussion","content":"\u003cp\u003eThis study examined how transplant-specific pulmonary symptom burden and psychological distress are linked to multiple indicators of quality of life in long-term lung transplant recipients. Three main findings emerged. First, higher pulmonary symptom burden was consistently associated with poorer quality of life across generic, transplant specific, and respiratory specific measures. Second, a composite psychological distress index showed strong associations with quality of life, particularly with generic health-related quality of life. Third, psychological distress partially mediated the association between pulmonary symptom burden and selected quality of life outcomes, especially the EQ-5D Index Value and the SF-36 overall score.\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003ePulmonary symptom burden and quality of life\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eThe observed levels of pulmonary symptoms were in the low to moderate range on average, yet even within this restricted spectrum symptom burden was robustly related to quality of life. Higher scores on the LT-QoL Pulmonary Symptoms scale were associated with worse EQ-5D outcomes, lower LT-QoL General Quality of Life, poorer SF-36 health status, and markedly worse disease specific respiratory status on the SGRQ. This pattern is consistent with prior work using the LT-QoL and other instruments, which has shown that residual dyspnea, cough, and respiratory limitations remain key determinants of health-related quality of life after lung transplantation, even among clinically stable survivors [1-4,7,10-12,25,26].\u003c/p\u003e\n\u003cp\u003eThe very strong correlation between LT-QoL Pulmonary Symptoms and SGRQ Total supports the convergent validity of the LT-QoL pulmonary domain as a concise marker of respiratory health impairment [7-9, 25]. At the same time, the substantial associations with both EQ-5D indices and the SF-36 overall score underline that pulmonary symptoms are not confined to the respiratory domain but permeate patients\u0026rsquo; broader perceptions of physical functioning, energy, and everyday life [1-4,6-8,10-12,25,26]. These findings are compatible with systematic reviews showing that, although lung transplantation improves health-related quality of life compared with pre-transplant status, many recipients continue to experience persistent limitations several years after surgery, with lung-related symptoms among the strongest correlates of impaired quality of life [1-5].\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003ePsychological distress as a parallel and partial mediator\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eThe psychological distress index, integrating HADS Anxiety and Depression with the LT-QoL Anxiety/Depression and Health Distress subscales, showed good internal consistency (Cronbach\u0026rsquo;s \u003cem\u003ealpha\u003c/em\u003e = .84 for standardized items) and behaved as a coherent marker of transdiagnostic emotional burden. As expected, higher distress was associated with lower EQ-5D Index Value and EQ-VAS scores, lower LT-QoL General Quality of Life, and worse SF-36 health-related quality of life. This aligns with prior work in lung and other solid organ transplant recipients, where elevated anxiety and depressive symptoms have been repeatedly linked to poorer quality of life and worse self-rated health [3,18-23,32].\u003c/p\u003e\n\u003cp\u003eEarlier studies have also documented that psychosocial vulnerability and distress are associated with more severe physical symptoms and physical impairment [19], more distressing treatment-related symptom experiences and lower adherence [20,23,24], higher rates of nonadherence across organ types [24], and in some cohorts, higher post-transplant mortality or worse composite outcomes [21,22,32]. A meta-analysis found no robust association between pretransplant anxiety/depression scores and posttransplant survival [32], which underlines that psychological distress may be more closely tied to functional outcomes and perceived health status than to hard survival endpoints.\u0026nbsp;Our findings add to this literature by explicitly modeling psychological distress as a pathway linking pulmonary symptoms with quality of life rather than treating distress only as a parallel correlate.\u003c/p\u003e\n\u003cp\u003eIn the hierarchical regression models, pulmonary symptom burden and psychological distress made partly independent contributions to quality of life. For the SF-36 overall score, both predictors had large and comparable standardized effects, together explaining over half of the variance. For the EQ-5D Index Value, psychological distress emerged as the more robust independent predictor, whereas for the EQ-VAS and transplant-specific general quality of life the association with pulmonary symptoms was stronger and the additional contribution of psychological distress was weaker or borderline significant. This pattern suggests that patients\u0026rsquo; cognitively integrated evaluations of health status, such as those captured by the EQ-5D Index Value and SF-36, may be particularly sensitive to emotional distress, whereas more immediate, global self-ratings and disease specific evaluations may be driven more directly by symptom burden.\u003c/p\u003e\n\u003cp\u003eThe mediation analyses further clarified these relationships. For the SF-36 overall score, psychological distress carried a significant part of the association between pulmonary symptom burden and health-related quality of life, while a substantial direct effect of pulmonary symptoms remained. This supports a dual pathway model, in which respiratory symptoms worsen quality of life both directly, through physical limitations and discomfort, and indirectly, by increasing emotional distress that in turn colors patients\u0026rsquo; perceptions of their health. For the EQ-5D Index Value, the total effect of pulmonary symptom burden was partly explained by the indirect path through psychological distress, and the direct effect in the mediation model fell below conventional significance, consistent with partial mediation. In contrast, for the EQ-VAS and LT-QoL General Quality of Life scales, indirect effects via psychological distress were smaller and did not consistently reach significance, indicating that these outcomes are more tightly linked to symptom burden itself than to distress.\u003c/p\u003e\n\u003cp\u003eThe sensitivity analysis with HADS-Anxiety and HADS-Depression entered as parallel mediators suggests that anxiety may be particularly important in carrying the impact of pulmonary symptoms, whereas depression alone contributes less uniquely when shared variance is accounted for. This is clinically plausible, given that breathlessness and fluctuating respiratory status are prototypical triggers of health-related anxiety and hypervigilance in chronic lung disease [18,29].\u003c/p\u003e\n\u003cp\u003eAn important conceptual consideration is the partial overlap between the psychological distress indicators and some of the quality of life outcomes. Both the EQ-5D Index Value and the SF-36 overall score include emotional components, and the LT-QoL Health Distress and Anxiety/Depression subscales capture related content. This conceptual proximity is likely to contribute to the strength of the associations between distress and generic QoL indices and may partly inflate estimates of the indirect effects. At the same time, the persistence of robust associations between pulmonary symptom burden and QoL after adjustment for distress, and the similar pattern of findings for more physically oriented outcomes such as the EQ-VAS, suggest that the interpretation of distress as a relevant parallel and partial mediator remains clinically meaningful.\u003c/p\u003e\n\u003cp\u003eThese findings also resonate with broader work on psychosocial risk and evaluation in transplantation, including structured tools such as the Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT) [28] and descriptive studies of psychosocial profiles among lung transplant candidates from the same center [25]. Together, these data underscore that psychosocial factors are integral to understanding post-transplant trajectories rather than an optional add-on [3,18-23,28,32]. Cluster-analytic work further suggests that a substantial subgroup of lung transplant recipients follows a trajectory of persistently high distress and impaired HRQoL, with little spontaneous improvement over time [1].\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eClinical implications\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eFrom a clinical perspective, the findings argue against a purely biomedical focus on lung function and rejection surveillance in long term follow-up. Even among relatively stable survivors several years after transplantation, modest elevations in pulmonary symptom burden and psychological distress were associated with meaningful decrements in quality of life. Systematic assessment of both domains is therefore warranted in routine care, using brief tools such as the LT-QoL pulmonary and emotional subscales together with generic quality of life measures (EQ-5D, SF-36) and brief anxiety/depression screens such as the HADS [7-12,15-17,33].\u003c/p\u003e\n\u003cp\u003eThe partial mediation by psychological distress suggests that interventions targeting distress could attenuate some of the quality of life impact of pulmonary symptoms, even if residual symptoms cannot be fully eliminated. Integrated models of care that combine optimization of medical management with psychological support, such as cognitive behavioral strategies for health anxiety, coping with breathlessness, and adjustment to chronic graft-related limitations, may therefore be particularly beneficial. At the same time, the strong direct effects of pulmonary symptoms across outcomes highlight that optimizing pulmonary status, rehabilitation, and symptom management remains fundamental for preserving quality of life [1-4,6-8,10-12,18,25,26,30,31].\u003c/p\u003e\n\u003cp\u003eEmerging concepts of prehabilitation and ongoing rehabilitation in solid organ transplant candidates and recipients, which emphasize a combination of physical training, nutritional optimization and psychosocial interventions to enhance resilience before and after surgery, are consistent with this dual focus [30,31]. Narrative reviews and consensus statements suggest that such multimodal programs are feasible and may improve functional capacity and HRQoL, although high-quality randomized trials remain limited [30,31].\u003c/p\u003e\n\u003ch3\u003e\u003cstrong\u003eStrengths and limitations\u003c/strong\u003e\u003c/h3\u003e\n\u003cp\u003eKey strengths of this study include the use of a disease-specific instrument tailored to lung transplant recipients, alongside multiple generic and respiratory specific quality of life measures [1-4,7-12,25,26,33], and the explicit modelling of psychological distress as a composite mediator. Using a composite index allowed us to capture shared variance across anxiety, depression and health-related distress without relying on arbitrary cut offs for any single scale [3,6,15-17,18-23,32,33]. The analytic strategy combined hierarchical regression with structural equation modelling, providing converging evidence on direct and indirect pathways.\u003c/p\u003e\n\u003cp\u003eSeveral limitations should be acknowledged. First, the cross-sectional design precludes causal inference. Although the hypothesized direction from pulmonary symptoms to distress to quality of life is theoretically and clinically plausible, reverse and bidirectional influences are also likely [1-4,18-23,26,32,33]. For example, poorer perceived health and impaired HRQoL may increase psychological distress, which in turn may heighten symptom perception and symptom reporting. The mediation analyses therefore identify statistical indirect effects that are consistent with a dual pathway model, but they cannot establish temporal ordering or causal mediation.\u003c/p\u003e\n\u003cp\u003eSecond, there is conceptual overlap between the psychological distress index and some of the quality of life indices, particularly the EQ-5D Index and the SF-36 overall score, which include emotional components [10-12,15-17]. This overlap may inflate the strength of associations between distress and generic QoL. However, the robust associations observed between pulmonary symptoms and QoL after adjustment for distress, and the similar pattern of results for outcomes that are more strongly driven by physical status such as the EQ-VAS, argue against a purely artefactual explanation [1-4,7-12,18-23,25,26,33].\u003c/p\u003e\n\u003cp\u003eThird, the sample was recruited from a single transplant center and consisted of relatively long-term survivors, with a mean of nearly five years since transplantation. Patients with early post-transplant complications, those lost to follow-up and individuals with the most severe impairments are likely under represented. The recruitment strategy, which relied on attendees at routine outpatient visits and additional invitations by telephone or email, may also have preferentially included more engaged and better functioning patients [1-4,6,25,26,33]. As a result, the range of symptom burden and distress may be restricted, which would tend to underestimate true associations.\u003c/p\u003e\n\u003cp\u003eFourth, key variables were based on self-report questionnaires. Although these instruments have documented reliability and validity [7-12,15-17], responses may be influenced by current mood and reporting styles. The study did not include concurrent objective indicators such as lung function parameters, six-minute walk distance, chronic lung allograft dysfunction status or detailed comorbidity profiles, which would allow more fine-grained modelling of the links between physiological impairment, symptoms, distress and quality of life [1-4,6,18,21-23,25,26]. Future work should integrate patient reported outcomes with clinical and functional data to disentangle perceived from physiological impairment.\u003c/p\u003e\n\u003cp\u003eFifth, the psychological distress index aggregates heterogeneous emotional constructs. This approach improves reliability and parsimony, but may obscure potentially important differences between anxiety, depressive symptoms and health-related worry [3,6,18-23,32]. The parallel mediator analysis suggests that anxiety may be more closely tied to the impact of pulmonary symptoms than depression, but these findings require replication in larger samples.\u003c/p\u003e\n\u003cp\u003eSixth, the sample size for the structural equation models was modest relative to model complexity. Although we used bootstrap confidence intervals to increase robustness, estimates of indirect effects may still be unstable, and the mediation models should be viewed as exploratory. Finally, we examined multiple outcomes and conducted several related regression and mediation analyses without formal correction for multiple testing. In view of the exploratory nature of the study, we focused on the overall pattern of findings across outcomes and emphasized more robust and consistent effects, but some statistically significant results, particularly those with p values close to 0.05, should be interpreted with caution.\u003c/p\u003e\n\u003ch4\u003e\u003cstrong\u003eFuture directions\u003c/strong\u003e\u003c/h4\u003e\n\u003cp\u003eFuture research should build on these findings in several ways. Longitudinal studies with repeated assessments of symptoms, distress, and quality of life could clarify the temporal dynamics and test whether changes in distress mediate the impact of evolving pulmonary status on subsequent quality of life [1-4,18,21-23,26,32,33]. Incorporating objective clinical indicators and biomarkers would help disentangle perceived from physiological impairment and might identify subgroups in whom subjective distress is disproportionately high relative to clinical status [16,18,21-23,32].\u003c/p\u003e\n\u003cp\u003eIntervention studies are also needed to examine whether targeted psychological or integrated rehabilitation interventions can effectively reduce distress and improve quality of life among lung transplant recipients with elevated symptom burden, building on existing evidence for pulmonary rehabilitation and cognitive behavioral approaches in chronic lung disease and transplantation [3,18-23,29-31,32]. Finally, multi-center studies using harmonized lung-transplant-specific and generic instruments, including the LT-QoL, EQ-5D, and SF-36, could test the robustness of the present findings across healthcare systems and patient populations and inform the development of routine, low burden tools for monitoring both physical and psychological outcomes in long-term post-transplant care [1-4,7,10-12,26,33].\u0026nbsp;\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cul\u003e\n \u003cli\u003e\u003cstrong\u003eEQ-5D-5L\u003c/strong\u003e - EuroQol 5-Dimension, 5-Level questionnaire\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eEQ-5D Index Value\u003c/strong\u003e - preference-based index derived from EQ-5D-5L health states\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eEQ-VAS\u003c/strong\u003e - EQ-5D Visual Analogue Scale\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eHADS\u003c/strong\u003e - Hospital Anxiety and Depression Scale\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eHRQoL\u003c/strong\u003e - Health-related quality of life\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eLT-QoL\u003c/strong\u003e - Lung Transplant Quality of Life questionnaire\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003ePROs\u003c/strong\u003e - Patient-reported outcomes\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eQoL\u003c/strong\u003e - Quality of life\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eSF-36\u003c/strong\u003e - 36-Item Short Form Health Survey\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eSGRQ\u003c/strong\u003e - St George\u0026rsquo;s Respiratory Questionnaire\u003c/li\u003e\n \u003cli\u003e\u003cstrong\u003eSIPAT\u003c/strong\u003e - Stanford Integrated Psychosocial Assessment for Transplantation\u003c/li\u003e\n\u003c/ul\u003e"},{"header":"Declarations","content":"\u003cp\u003e\u003cstrong\u003eEthics approval and consent to participate\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis retrospective cross-sectional study used anonymized data collected within a broader research project on lung transplant recipients, which was approved by the Independent Bioethics Committee for Scientific Research at the Medical University of Gdańsk, Poland. The present analyzes were based on questionnaire and clinical data collected during routine outpatient follow-up and did not modify patient management.\u003c/p\u003e\n\u003cp\u003eAll participants received information about the purpose and procedures of the broader research project and provided informed consent before completing the questionnaires (in written form during clinic visits or electronically or verbally for remote completion). Data were anonymized prior to analysis. All procedures were conducted in accordance with the ethical approval, institutional regulations, applicable data protection rules and the principles of the Declaration of Helsinki.\u003c/p\u003e\n\u003cp\u003eAll lung grafts in this cohort were procured and allocated via the national Polish transplantation system and the Department of Cardiac and Vascular Surgery, University Clinical Center in Gdańsk. Organs were obtained in accordance with Polish law and international ethical guidelines, including the Declaration of Istanbul. No organs or tissues were procured from prisoners at any stage of the transplantation process.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConsent for publication\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable. The manuscript does not contain any individual person\u0026rsquo;s identifiable data in any form (including images, case descriptions or videos).\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAvailability of data and materials\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe datasets generated and analyzed during the current study are not publicly available due to patient privacy and institutional data protection regulations but are available from the corresponding author on reasonable request.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompeting interests\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThe authors declare that they have no competing interests.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eFunding\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eThis research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; contributions\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eAS conceived and designed the study, coordinated data collection, performed the statistical analyses, interpreted the data and drafted the manuscript. SŻ contributed to patient recruitment, coordination of questionnaire completion during follow-up visits and acquisition of clinical data. WK contributed to the clinical interpretation of the findings and critically revised the manuscript for important intellectual content. JW provided clinical oversight of the lung transplant program and critically reviewed and approved the final version of the manuscript. All authors read and approved the final manuscript.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors\u0026rsquo; information\u003c/strong\u003e\u003c/p\u003e\n\u003cp\u003eNot applicable.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\n \u003cli\u003eSeiler A, Klaghofer R, Ture M, Komossa K, Martin-Soelch C, Jenewein J. A systematic review of health-related quality of life and psychological outcomes after lung transplantation. \u003cem\u003eJ Heart Lung Transplant.\u003c/em\u003e 2016;35(2):195-202.\u003c/li\u003e\n \u003cli\u003eSinger JP, Singer LG. Quality of life in lung transplantation. \u003cem\u003eSemin Respir Crit Care Med.\u003c/em\u003e 2013;34(3):421-430.\u003c/li\u003e\n \u003cli\u003eSinger JP, Katz PP, Soong A, Shrestha P, Huang D, Ho J, et al. Effect of Lung Transplantation on Health-Related Quality of Life in the Era of the Lung Allocation Score: A U.S. Prospective Cohort Study. \u003cem\u003eAm J Transplant.\u003c/em\u003e 2017;17(5):1334-1345.\u003c/li\u003e\n \u003cli\u003eRaguragavan A, Jayabalan D, Saxena A. Health-related Quality of Life Outcomes Following Single or Bilateral Lung Transplantation: A Systematic Review. \u003cem\u003eTransplantation\u003c/em\u003e. 2023;107(4):838-848.\u003c/li\u003e\n \u003cli\u003eRaguragavan A, Jayabalan D, Saxena A. Health-related quality of life following lung transplantation for cystic fibrosis: A systematic review. \u003cem\u003eClinics (Sao Paulo).\u003c/em\u003e 2023;78:100182.\u003c/li\u003e\n \u003cli\u003eGuo S, Jia Y, Wang R, Sun J, Liu H. Psychological distress and self-psychological adjustment methods of lung transplant recipients: an overview of systematic reviews. \u003cem\u003eBMC Psychol.\u0026nbsp;\u003c/em\u003e2025;13(1):884.\u003c/li\u003e\n \u003cli\u003eSinger JP, Soong A, Chen J, Shrestha P, Zhuo H, Gao Y, et al. Development and Preliminary Validation of the Lung Transplant Quality of Life (LT-QOL) Survey. \u003cem\u003eAm J Respir Crit Care Med.\u003c/em\u003e 2019;199(8):1008-1019.\u003c/li\u003e\n \u003cli\u003eJones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George\u0026rsquo;s Respiratory Questionnaire. \u003cem\u003eAm Rev Respir Dis.\u0026nbsp;\u003c/em\u003e1992;145(6):1321-1327.\u003c/li\u003e\n \u003cli\u003eKuźniar T, Patkowski J, Liebhart J, Wytrychowski K, Dobek R, Ślusarz R, et al. Validation of the Polish version of St. George\u0026rsquo;s respiratory questionnaire in patients with bronchial asthma. \u003cem\u003ePneumonol Alergol Pol.\u003c/em\u003e 1999;67(11-12):497-503.\u003c/li\u003e\n \u003cli\u003eWare JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. \u003cem\u003eMed Care.\u003c/em\u003e 1992;30(6):473-483.\u003c/li\u003e\n \u003cli\u003eTylka J, Piotrowicz R. Kwestionariusz oceny jakości życia SF-36 - wersja polska [Quality of life questionnaire SF-36 - Polish version]. \u003cem\u003eKardiol Pol.\u003c/em\u003e 2009;67(10):1166-1169.\u003c/li\u003e\n \u003cli\u003eHerdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). \u003cem\u003eQual Life Res.\u003c/em\u003e 2011;20(10):1727-1736.\u003c/li\u003e\n \u003cli\u003eGolicki D, Jakubczyk M, Graczyk K, Niewada M. Valuation of EQ-5D-5L Health States in Poland: the First EQ-VT-Based Study in Central and Eastern Europe. \u003cem\u003ePharmacoeconomics\u003c/em\u003e. 2019;37(9):1165-1176.\u003c/li\u003e\n \u003cli\u003eGolicki D. General population reference values for the EQ-5D-5L index in Poland: estimations using a Polish directly measured value set. \u003cem\u003ePol Arch Intern Med.\u003c/em\u003e 2021;131(5):484-486.\u003c/li\u003e\n \u003cli\u003eZigmond AS, Snaith RP. The hospital anxiety and depression scale. \u003cem\u003eActa Psychiatr Scand.\u003c/em\u003e 1983;67(6):361-370.\u003c/li\u003e\n \u003cli\u003eSnaith RP. The Hospital Anxiety And Depression Scale. \u003cem\u003eHealth Qual Life Outcomes.\u003c/em\u003e 2003;1:29.\u003c/li\u003e\n \u003cli\u003eMihalca AM, Pilecka W. The factorial structure and validity of the Hospital Anxiety and Depression Scale (HADS) in Polish adolescents. \u003cem\u003ePsychiatr Pol.\u0026nbsp;\u003c/em\u003e2015;49(5):1071-1088.\u003c/li\u003e\n \u003cli\u003eDew MA, DiMartini AF, DeVito Dabbs AJ, Fox KR, Myaskovsky L, Posluszny DM, et al. Onset and risk factors for anxiety and depression during the first 2 years after lung transplantation. \u003cem\u003eGen Hosp Psychiatry.\u003c/em\u003e 2012;34(2):127-138.\u003c/li\u003e\n \u003cli\u003eDe Vito Dabbs A, Dew MA, Stilley CS, Manzetti J, Zullo T, McCurry KR, et al. Psychosocial vulnerability, physical symptoms and physical impairment after lung and heart-lung transplantation. \u003cem\u003eJ Heart Lung Transplant.\u003c/em\u003e 2003;22(11):1268-1275.\u003c/li\u003e\n \u003cli\u003eKugler C, Fischer S, Gottlieb J, Tegtbur U, Welte T, Goerler H, et al. Symptom experience after lung transplantation: impact on quality of life and adherence. \u003cem\u003eClin Transplant.\u003c/em\u003e 2007;21(5):590-596.\u003c/li\u003e\n \u003cli\u003eSmith PJ, Blumenthal JA, Trulock EP, Freedland KE, Carney RM, Davis RD, et al. Psychosocial Predictors of Mortality Following Lung Transplantation. \u003cem\u003eAm J Transplant.\u003c/em\u003e 2016;16(1):271-277.\u003c/li\u003e\n \u003cli\u003eSmith PJ, Snyder LD, Palmer SM, Hoffman BM, Stonerock GL, Ingle KK, et al. Depression, social support, and clinical outcomes following lung transplantation: a single-center cohort study. \u003cem\u003eTranspl Int.\u003c/em\u003e 2018;31(5):495-502.\u003c/li\u003e\n \u003cli\u003eWessels-Bakker MJ, van de Graaf EA, Kwakkel-van Erp JM, Heijerman HG, Cahn W, Schappin R. The relation between psychological distress and medication adherence in lung transplant candidates and recipients: A cross-sectional study. \u003cem\u003eJ Clin Nurs.\u003c/em\u003e 2022;31(5-6):716-725.\u003c/li\u003e\n \u003cli\u003eDew MA, DiMartini AF, De Vito Dabbs A, Myaskovsky L, Steel J, Unruh M, et al. Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. \u003cem\u003eTransplantation\u003c/em\u003e. 2007;83(7):858-873.\u003c/li\u003e\n \u003cli\u003eKarolak W, Stańska A, Wojarski J, Shinde R, Ciak E, Polishchuk A, et al. Demographic and Psychosocial Characteristics of Lung Transplant Candidates: Single-Center Analysis. \u003cem\u003eTransplant Proc.\u0026nbsp;\u003c/em\u003e2022;54(4):1078-1081.\u003c/li\u003e\n \u003cli\u003eSingh TP, Hsich E, Cherikh WS, Perch M, Hayes D Jr, Lewis A, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: 2025 Annual Report of Heart and Lung Transplantation. \u003cem\u003eJ Heart Lung Transplant.\u003c/em\u003e 2025;44(12):1857-1873.\u003c/li\u003e\n \u003cli\u003eWeill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014 - an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. \u003cem\u003eJ Heart Lung Transplant.\u003c/em\u003e 2015;34(1):1-15.\u003c/li\u003e\n \u003cli\u003eMaldonado JR, Dubois HC, David EE, Sher Y, Lolak S, Dyal J, et al. The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): a new tool for the psychosocial evaluation of pre-transplant candidates. \u003cem\u003ePsychosomatics\u003c/em\u003e. 2012;53(2):123-132.\u003c/li\u003e\n \u003cli\u003eYohannes AM, Junkes-Cunha M, Smith J, Vestbo J. Management of Dyspnea and Anxiety in Chronic Obstructive Pulmonary Disease: A Critical Review. \u003cem\u003eJ Am Med Dir Assoc.\u003c/em\u003e 2017;18(12):1096.e1-1096.e17.\u003c/li\u003e\n \u003cli\u003eQuint EE, Ferreira M, van Munster BC, Nieuwenhuijs-Moeke G, Te Velde-Keyzer C, Bakker SJL, et al. Prehabilitation in Adult Solid Organ Transplant Candidates. \u003cem\u003eCurr Transplant Rep.\u003c/em\u003e 2023;10(2):70-82.\u003c/li\u003e\n \u003cli\u003eAnnema C, De Smet S, Castle EM, Overloop Y, Klaase JM, Janaudis-Ferreira T, et al. European Society of Organ Transplantation (ESOT) Consensus Statement on Prehabilitation for Solid Organ Transplantation Candidates. \u003cem\u003eTranspl Int.\u003c/em\u003e 2023;36:11564.\u003c/li\u003e\n \u003cli\u003eCourtwright AM, Salomon S, Lehmann LS, Wolfe DJ, Goldberg HJ. The Effect of Pretransplant Depression and Anxiety on Survival Following Lung Transplant: A Meta-analysis. \u003cem\u003ePsychosomatics\u003c/em\u003e. 2016;57(3):238-245.\u003c/li\u003e\n \u003cli\u003eStańska A, Karolak W, et al. Polish adaptation of the Lung Transplant Quality of Life (LT-QoL) questionnaire. \u003cem\u003eRes Sq [Preprint]\u003c/em\u003e. 2024. Available from: https://www.researchsquare.com/article/rs-8129195/v1. Preprint, in review.\u0026nbsp;\u003c/li\u003e\n\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"bmc-pulmonary-medicine","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"pulm","sideBox":"Learn more about [BMC Pulmonary Medicine](http://bmcpulmmed.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/pulm/default.aspx","title":"BMC Pulmonary Medicine","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true},"keywords":"Anxiety, Depression, Lung Transplantation, Quality of Life, Patient-Reported Outcome Measures","lastPublishedDoi":"10.21203/rs.3.rs-8290982/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8290982/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003e\u003cstrong\u003eBackground:\u003c/strong\u003e Lung transplant recipients often live for years with residual respiratory symptoms and psychological distress, but the pathways through which these factors affect quality of life (QoL) are not fully understood. We examined how transplant-specific pulmonary symptom burden and psychological distress relate to generic and transplant-specific QoL in long-term lung transplant recipients.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eMethods:\u003c/strong\u003e In this cross-sectional study, 76 adult lung transplant recipients from a single centre completed the Lung Transplant Quality of Life (LT-QoL) questionnaire, EQ-5D-5L, SF-36, St George’s Respiratory Questionnaire (SGRQ) and Hospital Anxiety and Depression Scale (HADS). A composite psychological distress index was derived from HADS-Anxiety, HADS-Depression and the LT-QoL Anxiety/Depression and Health Distress subscales. Associations were examined using Pearson correlations, hierarchical linear regression (adjusting for age, sex and time since transplant) and mediation models with psychological distress as a mediator between pulmonary symptoms and QoL outcomes.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eResults:\u003c/strong\u003e Pulmonary symptom burden (LT-QoL Pulmonary Symptoms) was in the low-moderate range yet showed robust correlations with poorer generic, transplant-specific and respiratory-specific QoL (|r| up to .82). The psychological distress index demonstrated good internal consistency (α = .84) and was strongly associated with worse EQ-5D, SF-36 and LT-QoL General QoL scores. In regression models, pulmonary symptoms and psychological distress independently predicted SF-36 overall QoL (R² = .55), whereas psychological distress was the stronger predictor of EQ-5D Index Value. Mediation analyses indicated that psychological distress partially mediated the association between pulmonary symptoms and SF-36 and EQ-5D Index Value, while effects on EQ-VAS and LT-QoL General QoL were largely direct.\u003c/p\u003e\n\u003cp\u003e\u003cstrong\u003eConclusions:\u003c/strong\u003eEven modest pulmonary symptom burden and psychological distress are tightly linked to QoL years after lung transplantation. Routine follow-up should include brief assessment of both domains, and integrated care models that combine optimisation of pulmonary status with targeted psychological support may be needed to preserve long-term QoL in lung transplant recipients.\u003c/p\u003e","manuscriptTitle":"Pulmonary Symptoms and Psychological Distress as Correlates and Mediators of Quality of Life in Lung Transplant Recipients: A Cross- sectional Study","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-01-08 13:57:03","doi":"10.21203/rs.3.rs-8290982/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"editorInvitedReview","content":"","date":"2026-01-12T19:27:00+00:00","index":"hide","fulltext":""},{"type":"reviewerAgreed","content":"314895953661005450250086974952767509844","date":"2026-01-09T16:38:26+00:00","index":"hide","fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-01-07T03:58:44+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-01-05T12:05:41+00:00","index":"","fulltext":""},{"type":"editorInvited","content":"","date":"2025-12-12T14:07:41+00:00","index":"","fulltext":""},{"type":"checksComplete","content":"","date":"2025-12-11T09:39:01+00:00","index":"","fulltext":""},{"type":"submitted","content":"BMC Pulmonary Medicine","date":"2025-12-11T08:58:33+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"bmc-pulmonary-medicine","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"pulm","sideBox":"Learn more about [BMC Pulmonary Medicine](http://bmcpulmmed.biomedcentral.com/)","snPcode":"","submissionUrl":"https://www.editorialmanager.com/pulm/default.aspx","title":"BMC Pulmonary Medicine","twitterHandle":"BMC_series","acdcEnabled":true,"dfaEnabled":false,"editorialSystem":"em","reportingPortfolio":"BMC Series","inReviewEnabled":true,"inReviewRevisionsEnabled":true}}],"origin":"","ownerIdentity":"db7ba5d1-4e5e-4ac8-bf52-82d77ed12ddf","owner":[],"postedDate":"January 8th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"under-review","subjectAreas":[],"tags":[],"updatedAt":"2026-01-08T13:57:04+00:00","versionOfRecord":[],"versionCreatedAt":"2026-01-08 13:57:03","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8290982","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8290982","identity":"rs-8290982","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}